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Despite advancements in treatment techniques, the five-year survival rate for oral
cancer has not increased significantly over the past 40 years.  This is likely due to the fact
that oral cancer is generally not diagnosed until it has reached advanced stages when
treatment is more difficult and debilitating and the five-year survival rate for patients is
poor.  Currently, diagnosis of oral cancer is achieved through visual identification and
recognition, which relies on the expertise of the treating clinician.
Optical techniques could potentially improve diagnosis and detection of oral
cancer by allowing objective assessment of the molecular and biochemical changes in
neoplastic tissue relative to normal tissue.  Successful application and validation of these
viii
techniques will lead to better screening and early detection of premalignant lesions,
reducing the incidence of cancer in high-risk individuals.
The work presented in this dissertation demonstrates the development of a
molecular-specific fluorescent contrast agent in combination with fluorescence
spectroscopy and confocal microscopy that could potentially be used as a diagnostic or
screening technique in the oral cavity.  The specificity of the contrast agent for epidermal
growth factor receptor, a molecular marker overexpressed in oral cancer, was
demonstrated using in vitro biological models, along with the ability to penetrate into
multiple layers of epithelial cells using permeability-enhancing agents.  The contrast
agent was also evaluated in ex vivo biopsy samples, using fresh tissue slices from paired
clinically abnormal and clinically normal biopsy samples.  These experiments revealed
that it may be possible to use the ratio of the mean fluorescence intensity from an
abnormal to normal site or the surface mean fluorescence intensity as a diagnostic criteria
to separate normal tissue from moderate dysplasia and cancer.  The use of a simple
spectroscopy system in conjunction with the contrast agent was also demonstrated, which
would be ideal as an inexpensive diagnostic tool that could be used without specialized
training.  Finally, issues which must be considered for in vivo use of the contrast agent
were explored.  Together, the research presented in this dissertation lays the groundwork
for the development of a tool that could be used in diagnosis of oral cancer.
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 The use of molecular-specific contrast agents in combination with noninvasive
optical detection has the potential to significantly improve early diagnosis and treatment
of oral cancer.  Molecular-specific contrast agents not only provide increased specificity
for precancer and cancer by targeting markers which are specific to precancer and cancer,
but also have the potential to aid early detection by targeting markers which are
expressed early in the transformation process.  Optical methods allow for noninvasive
detection of the optical signature provided by the contrast agents, providing real-time
diagnosis and eliminating the need for painful biopsies.  Fluorescence spectroscopy is a
noninvasive, near real-time method of providing quantitative standard for cancer
detection.  In addition to contributing to patient comfort, the use of spectroscopy
eliminates the subjectivity of visual recognition for diagnosis and the need for clinical
expertise in detection of oral cancer.  In this dissertation, I will show that the combination
of molecular-specific contrast agents and noninvasive optical detection increases optical
contrast between normal and neoplastic tissue and aids in early detection of oral cancer.
Besides prevention, early diagnosis is one of the most important elements in treatment of
cancer as it greatly improves the five-year survival rate of patients and minimizes the
severity of treatment necessary to eradicate the cancer.   The development of effective
2
screening techniques in the oral cavity is particularly critical since there are currently no
methods of screening for oral cancer beyond visual recognition.
1.2 SPECIFIC AIMS
The primary goal of my research was to develop a potential tool for screening or
diagnosis of oral cancer using a molecular-specific fluorescence contrast agent that would
preferentially target precancerous and cancerous tissue and a fluorescence spectroscopy
system.  In order to accomplish this, I set the following as my specific aims:
(1) Investigate potential markers specific to oral precancer and cancer and
develop methods of specifically targeting these markers.  Two markers in particular were
focused on for targeting: cytokeratins, as an intracellular marker, and epidermal growth
factor receptor (EGFR), as an extracellular marker.  Other markers of oral cancer were
also investigated as potential alternatives.
(2) Develop contrast agents based on probe molecules specific to the markers for
oral precancer and cancer conjugated to fluorescent markers.  The probe molecules were
antibodies against the marker of interest.  The fluorescent marker was a long-wavelength
fluorescent dye.
(3) Design and build a simple and inexpensive spectroscopy system to detect the
fluorescence emission spectra from the contrast agent.  The spectroscopy system targeted
the wavelength specific to the fluorescent marker, and measured the emission spectra of
the marker.  The system consisted of a light source which provided the proper
3
wavelength light for excitation of the fluorescent contrast agent, a miniature spectrometer
from Ocean Optics, and a fiber optic probe.
(4) Validate the contrast agent in two biological models.  First, monolayers of
cancerous oral epithelial cells were used to test the specificity and relative binding
efficiencies of the contrast agents.  Second, three-dimensional multilayer tissue constructs
consisting of multiple layers of epithelial cells embedded in collagen were used as a
model system for tissue in vivo to determine the binding efficiencies and penetration
depth of the contrast agent.  In the penetration depth studies, the need for permeability-
enhancing agents was investigated.  Permeability-enhancing agents which could be added
to the contrast agent to improve penetration depth include dimethyl sulfoxide (DMSO),
polyvinylpyrroliodone (PVP), and bovine serum albumin (BSA).  The ability of the
spectroscopy system to detect the contrast agents in the multilayer tissue construct was
also investigated.
(5) Test the contrast agent and spectroscopy system were in living normal and
neoplastic oral tissue using fresh transverse sections of biopsies obtained from consenting
patients at the University of Texas M.D. Anderson Cancer Center.  The sections, known
as fresh tissue slices, were maintained in culture until application of the contrast agents so
that the binding in living tissue could be studied.
(6) Investigate the possibility of in vivo use of the contrast agent.  In addition to
investigating previous in vivo work done by other investigators using similar systems,
4
physiological labeling and standard cytotoxicity assays with the contrast agent were
performed.
1.3 DISSERTATION OVERVIEW
The second chapter provides the motivation and background for this dissertation,
including an overview of the anatomy and pathology of the oral cavity and a summary of
molecular markers of oral neoplasia, contrast agents currently in use, optical diagnostic
techniques of oral neoplasia, and permeability-enhancing agents.  The third chapter
includes portions of a paper published in Photochemistry and Photobiology,
demonstrating the efficacy of the contrast agent in in vitro cell monolayer models,
multilayer tissue constructs in the presence of permeability-enhancing agents, and its
potential to distinguish abnormal from normal tissue in fresh tissue slices prepared from
paired biopsy samples from the oral cavity.  The fourth chapter expands on the possibility
of using the fluorescence intensity of the contrast agent in diagnosing oral cancer using
paired biopsies obtained from 17 consenting patients at the University of Texas M.D.
Anderson Cancer Center.  The fifth chapter describes a simple and inexpensive
fluorescence spectroscopy system that can be used to detect the optical signature of the
contrast agent from labeled cells in multilayer tissue constructs.  The sixth chapter
explores issues which must be considered for in vivo use of the contrast agent, including
cytotoxicity of the fluorescent dye.  The last chapter will provide summary and





This chapter will provide the necessary context to understand this dissertation.
First, the motivation for the research presented in the dissertation will be discussed.
Second, an overview of the anatomy and the pathology of the oral cavity will be
provided.  Molecular markers that could be used to detect precancerous and cancerous
lesions will then be discussed.  Contrast agents currently in use for detection of neoplasia
will then be reviewed.  Finally, an overview of optical diagnostic techniques and
permeability enhancing agents will be presented.
2.2 MOTIVATION
In the United States, it is predicted that approximately 30,000 new cases of oral
cancer are diagnosed each year (1, 2), with approximately 7,200 deaths due to oral cancer
in the year 2003 (1).  Despite the fact that the oral cavity is in an easily accessible area for
screening, the mortality due to oral cancer accounts for approximately 1.7% of mortality
due to cancer overall (3).  Worldwide, the problem is even greater, with oral and
pharyngeal cancers ranking fifth in prevalence (4) and accounting for approximately 50%
of all cases of cancers in males in India (5).  The five-year survival rate for patients
diagnosed with oral cancer at all stages is approximately 50% (1, 6); however, this
number dramatically shifts depending on the stage of the cancer at the time of diagnosis.
6
The five-year survival rate varies from 9-100% depending on the invasion and metastasis
of the tumor (2, 3). Table 2-1 summarizes the five-year survival rate as a function of
tumor stage.
Table 2-1 Five-year survival rate of oral cancer as related to stage of tumor.






Five-year survival rates complied from (2, 3)
Early diagnosis not only improves the five-year survival rate of patients, but also
results in less radical and debilitating treatments, thus improving the quality of life for
patients (2).  Over the past 40 years, the five-year survival rate for oral cancer has not
significantly increased although treatment techniques have advanced (7, 8).  Further, the
five-year survival rate for oral cancer is among the lowest of the major cancers
worldwide (8).  This is likely due to the fact that oral cancer is generally not diagnosed
until it has reached advanced stages when treatment is more difficult and debilitating and
the five-year survival rate for patients is poor.  Currently, diagnosis of oral cancer is
achieved through visual identification and recognition, which relies on the experience of
the treating clinician.
Optical techniques could potentially improve diagnosis and detection of oral
cancer by allowing objective assessment of the molecular and biochemical changes in
neoplastic tissue relative to normal tissue.  Successful application and validation of these
7
techniques will lead to better screening and early detection of premalignant lesions,
reducing the incidence of cancer in high-risk individuals.
2.3 ANATOMY OF THE ORAL CAVITY
Anatomically, the oral cavity can be divided into two major regions, the oral
vestibule and the oral cavity proper.  The vestibule is the opening to the oral cavity and
consists of the space between the teeth and buccal gingiva and the lips and cheeks.  The
oral cavity proper consists of the hard and soft palate, which form the roof of the oral
cavity, and the tongue, which forms the floor of the oral cavity (9).  Figure 2-1 illustrates
the regions of the oral cavity.
Figure 2-1 Cartoon drawing of the regions of the oral cavity.  Figure modified from (10).
The oral cavity is lined by a mucosal membrane that consists of an outer layer of
stratified squamous epithelium and an underlying layer of dense connective tissue known
as the lamina propria (11).  A submucosa beneath the connective tissue can also occur,
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cavity and the function of the site, structural modifications occur in the epithelium and
connective tissue.  There are three histological types of epithelia in the oral cavity:
masticatory mucosa, which is a tough mucosa found in the gingiva and hard palate, lining
mucosa, which is a flexible mucosa found in the lips, cheek, vestibule, alveolar mucosa,
soft palate, floor of mouth, and inferior surface of the tongue, and specialized mucosa,
which is a mix of the masticatory and lining mucosa found on the dorsum of the tongue
(11).
The epithelium of the oral cavity can be either keratinized, as with the masticatory
mucosa, or nonkeratinized, as with the lining mucosa, and provides protection against
mechanical, microbial, and chemical damage (11).  The epithelium can further be broken
down in more layers.  From the basement membrane to the superficial epithelium, this
consists of the basal layer, spinous layer, granular layer, and keratinized layer for
keratinized epithelium and the basal layer, spinous layer, intermediate layer, and
superficial layer for nonkeratinized epithelium (11).  The basal layer consists of two to
three layers of the least-differentiated cells that are responsible for cell division and
production and are cuboidal or columnar in shape.  As the cells progress superficially in
the epithelium, they begin to express more keratins and increase in size.  In the granular
layer, the cells assume a flattened shaped with densely packed keratin filaments.  The
cells in the intermediate layer of nonkertanized epithelium also assume a flattened shape
and express increased keratin compared to basal cells.  Finally, at the most superficial
keratinized layer, the cells have thickened plasma membranes and contain densely packed
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keratin filaments and no organelles.  In the oral cavity, there tends to be a higher rate of
cell production but a reduced turnover time in both keratinized and nonkeratinized
epithelium as compared to the epidermis (11).
Within the oral cavity, the structure and appearance of the mucosa differs
depending on the exact site and the function of the site.  For example, an area exposed to
the functional demands of mechanical stress will be lined with masticatory mucosa while
an area which needs to withstand distention will be lined with lining mucosa.  The
difference in clinical appearance of the oral mucosa varies depending on the distribution
of superficial blood vessels, the type and thickness of the epithelium, composition of the
submucosa, pigmentation and appendages, surface features of the mucosa, functional
adaptations, and disease (11).  The thickness of the epithelial layer depends on the site
within the oral cavity, ranging from the thin layer of 190 µm +/- 40 µm of the floor of the
mouth to the thick layer of 580 µm +/- 90 µm of the buccal mucosa (11).
2.4 PATHOLOGY OF THE ORAL CAVITY
Diagnosis of disease in the oral cavity depends on clinical suspicion based visual
assessment and subsequent microscopic assessment after biopsy (12).  There is a
deficiency in the recognition of early lesions in the oral cavity, and this may be due to the
fact that the oral cavity is tended to by two different types of clinicians (13).  The dentist
is the primary clinician seen for routine treatment in the oral cavity and is familiar with
the anatomical region, but may not have specialized training in recognizing early cancer.
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By the time a lesion is recognized as cancer by a clinician without specialized training, it
generally has reached advanced stages.
Oral premalignancies often present as leukoplakia or erythroplakia.  Leukoplakia,
the most common form of oral precancer (2), is due to the biochemical process of
hyperkeratosis (12, 13) and is defined as a clinical white patch on the oral mucous
membrane that cannot be removed and cannot be classified as another disease entity.
Leukoplakia, however, can represent either a benign hyperkeratotic lesion or a dysplastic
changes indicative of a pre-invasive or invasive cancer (2) and red inflammation known
as erythroplakia exhibits the most significant cellular changes indicative of early cancer
(13).  Erythroplakia may be present with or without the keratinization that produces the
white leukoplakia and is often disregarded as innocuous because of lack of keratinization.
At time of clinical identification, erythroplakia is almost always associated with dysplasia
or carcinoma (2) and is the most common and primary color presentation of early
squamous cancer (13).
The development of invasive squamous cell carcinoma (SCC) can be outlined
using the progression of carcinoma in the cervix as a model as shown in Figure 2-2 (3).
Keratosis is caused by increased keratin production and commonly occurs in the oral
cavity due to irritation.  While keratosis is often a feature of early malignancy, the
relationship between benign keratosis and eventual development of carcinoma is
uncertain (3).
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Figure 2-2 Progression from normal epithelium to invasive SCC.  Recognized precursors
include dysplasia and carcinoma in situ.  The significance and relationship of benign
keratosis in the transformation process is less well understood (3).
 In the oral cavity, dysplasia and carcinoma in situ are well-recognized precursors
of invasive SCC, though there are various degrees of dysplasia that must be distinguished
when considering treatment options.  Mild dysplasia is not highly indicative of an early
malignant process and has the potential to resolve without treatment while severe
dysplasia can often coexist with carcinoma in situ and invasive carcinoma and could be
considered early malignancy rather than precancer (13).  The progression from normal













Figure 2-3 Cartoon of progression from normal through the stages of dysplasia to
invasive carcinoma.  Modified from (14).
When severe dysplasia or carcinoma has been diagnosed in the oral cavity, the
possibility of field cancerization or field changes in the remaining oral mucosa must be
considered.  The concept of field cancerization was developed when it was observed that
there is a high incidence of second primary cancers in patients with oral SCC, with 2-7%
of patients developing a second cancer within a year of initial treatment (12, 15).  The
development of multiple primary tumors can be explained by the etiology of oral cancer.
Large regions of the oral mucosa are exposed to the etiological agents that cause cancer
in the oral cavity, such as tobacco and alcohol, allowing for the possibility of independent
transformation of single epithelial cells in multiple locations (12, 15).  There is also the
possibility of a clonal cluster of cancer cells spreading within the oral cavity, either






















cancers.  Tumor tissue may also have a paracrine effect on adjacent normal tissue,
increasing its susceptibility to future development of carcinoma (12).
 Molecular changes in the oral mucosa that may predispose the patient to the
development of additional primary cancers are known as field changes (12).
Identification of predictive markers based on these molecular changes would have
significant prognostic and patient management implications.
SCC does not affect all areas of the oral cavity equally, with the lateral surfaces
and the underside of the tongue being the most often affected (3).  The high-risk areas of
oral SCC are the lateral tongue, the ventral tongue, the floor of the mouth, the soft palate,
and the tonsilar pillars (3).  The incidence of SCC by location is outlined in Table 2-2.
Table 2-2 Incidence of SCC by location in the oral cavity (3).
General Location Incidence Specific Location
Tongue 26% • Lateral surface
• Ventral surface
Oral pharynx 23% • Soft palate
• Tonsillar pillars
Lip 20% • Vermilion surface
Floor of mouth 17% • Floor of mouth
Gingiva 9% • Gingiva
Buccal mucosa 3% • Buccal mucosa
Hard Palate 2% • Hard palate
2.5 MOLECULAR MARKERS OF ORAL CANCER
Current pathological techniques involve microscopic examination of tissue, such
that detection and identification of cancer only occurs after disease onset (16) and
requires biopsy.  Molecular markers, however, can potentially act as early indicators of
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disease or the progression of disease (16).  In order to be effective, a molecular marker
must meet the following criteria: easily detectable, relevant across populations, and
useful in either early detection, identification of high-risk individuals, early detection of
recurrence, or as intermediate endpoints in chemoprevention (16).  As illustrated in
Figure 2-4, identifying a molecular marker early in the transformation process can
improve intervention efficacy and increase survival.
Figure 2-4 Cancer development and progression.  Identification of molecular makers
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Molecular markers can be broadly classified into genetic markers and their
protein products, proliferative markers, differentation markers, angiogenic markers,
apoptosis markers, migration markers, and extracellular and serum markers (15-20).
Genetic markers and their protein products can be further broken down into oncogenes,
tumor suppressors, genetic instability makers, and cell cycle regulation makers (15, 16,
18, 19).
Of course, the biology of tumor progression is not so simple that a single marker
can be used as an absolute positive indication for cancer; tumor progression is unique to
each individual and the specific type of tumor.  It is more likely that a set of molecular
markers will be needed for screening and early diagnosis of most cancers (17, 19).
However, even the use of a single molecular maker has the potential to aid early
diagnosis, reduce the subjectivity often associated with pathological diagnosis, and
reduce the need for clinical expertise in diagnosis.  Further, because of the probability of
field cancerization in oral cancer, molecular markers can be used to monitor patients for
second primary tumors after initial treatment.
2.5.1 Epidermal Growth Factor Receptor
An extracellular target which has been studied extensively in tumor progression is
epidermal growth factor receptor (EGFR).  EGFR is a 170 kDa transmembrane tyrosine
kinase receptor, part of the erbB subfamily of receptors.  The extracellular ligand binding
domain is anchored by a single transmembrane domain and intracellularly, EGFR
contains a juxta-membrane region, protein kinase domain, and carboxy-terminal region
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(21).  Six ligands bind EGFR: epidermal growth factor (EGF), transforming growth
factor-alpha (TGF-α), amphiregulin (AR), heparin-binding EGF-like growth factor,
betacellulin, cripto, and epiregulin (21).  These ligands have distinct expression patterns
during development and distinct isoelectric points, which suggests multiple functions of
EGFR that could be modulated by the environment (21).  A number of cellular events are
mediated by the activated receptor, including ion fluxes, phosphorylation events, gene
expression, DNA synthesis, and malignant transformation (21).
Malignant transformation is usually associated with overexpression of both EGFR
and its ligands; overexpression of ligand alone with normal receptor expression results in
hyperproliferation but not transformation (21).  Overexpression of EGFR has been
associated with a number of human malignancies including bladder, breast, cervix and
vulva, glioma, lung, and head and neck tumors (22-24).  EGFR mRNA expression can be
increased approximately 69-fold in malignant versus normal oral cavity tissue (21, 22);
however, elevated mRNA expression is not always seen (25) and increased mRNA may
instead be due to transcriptional or post-transcriptional modifications (24).  Further,
overexpression of EGFR is generally not due to amplification of the EGFR gene, which
is only seen in 5-20% of patients overexpressing EGFR (26-28).  This suggests that gene
amplification is not the only mechanism of EGFR overexpression, and the major
mechanism of overexpression develops post-transcriptionally or post-translationally (26-
28).
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Nouri et al found that 73% of the invasive oral squamous cell carcinomas they
studied showed strong expression of EGFR (23).  Other reports have estimated that 50-
98% of tumors in the oral cavity overexpress EGFR (27-31).  EGFR expression is
detected at all stages of carcinogenesis, from normal-early hyperplasia, dysplasia, and
invasive carcinoma (32, 33).  EGFR expression is elevated during the progression from
hyperplasia to dysplasia and increases during progression from dysplasia to invasive
squamous cell carcinoma (34).  Further, EGFR expression is elevated in normal
epithelium which is adjacent to tumor (34), regardless of tobacco and alcohol abuse (35).
EGFR expression is about 2-fold higher in histologically normal epithelia adjacent to
head and neck tumors than normal control epithelia from nonsmokers (34).  EGFR
expression in normal epithelia adjacent to tumor in patients who smoke and drink
excessively is higher than that in patients who do not smoke or drink (35).
Overexpression of EGFR in malignancy appears to be related to high rates of cell growth
and proliferation rather than DNA repair (22).
The correlation between EGFR expression and tumor staging, prognosis, and
relapse has also been investigated.  Overexpression of EGFR may not correlate strongly
with tumor staging, with a number of studies reporting no significant correlation between
receptor levels and tumor stage (27, 28, 36).  However, some studies have found that
tumor EGFR levels are correlated to the size of tumor (30, 31) and have shown that mean
values of EGFR increased with tumor size and advanced clinical stage (28).  In a
correlative study of patients with advanced head and neck squamous cell carcinoma
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(HNSCC) enrolled in a radiotherapy study, EGFR expression was a strong prognostic
indicator for overall survival and disease-free survival and was highly predictive for the
probability of local-regional relapse but not distant metastasis (36).
EGFR has been targeted for use in cancer therapeutic agents, with the belief that
inhibiting the tyrosine kinase receptor will inhibit cancer growth and terminal
differentiation (21) and possibly cause regression of precancerous lesions (37).  Targeting
generally involves the use of monoclonal antibodies which target the receptor and prevent
binding of ligand (21).  Soukos et al expanded on this by conjugating the antibody to a
photoactive molecule and demonstrated regression of premalignant lesions in the Syrian
golden hamster cheek model after i.v. injection of the conjugate and exposure to
therapeutic light (37).  In addition, they were able to visualize dysplasia in their model
using a conjugate of the antibody and fluorescent dye.
2.5.2 Cytokeratins
Cytokeratins are the intermediate filaments of epithelial cells, and are broken
down into two subclasses, acidic and neutral to basic.  The expression pattern of
intermediate filaments during embryologic development and differentiation parallels the
appearance of histologically distinct cell types in the embryo and adult, indicating that
cell types can be characterized based on their intermediate filament expression pattern
(38).  The cytokeratin profile of a tissue depends on the developmental stage, cell type,
tissue differentiation, and pathological modifications, making cytokeratins an excellent
marker for differentiation state (39), with rapidly proliferating cells expressing
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characteristic cytokeratins.  Intermediate filament typing is potentially useful in tumor
diagnosis, particularly in cases where tumors cannot be classified by conventional
procedures, and metastases appear to retain the intermediate filament expression typical
of the primary tumor (38).  All carcinoma cells contain cytokeratins regardless of degree
of differentiation, with different types of tumors expressing different amounts, types, and
arrangements of cytokeratins (38).  This indicates that the cytokeratin expression pattern
can be used to distinguish and even classify tumors.  However, the situation is more
complicated than simply typing for a single cytokeratin, since conflicting studies have
associated various cytokeratins with different stages of oral cancer.  Table 2-3 lists
cytokeratins by their association with tissue type according to the findings of different
groups.
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Table 2-3 Cytokeratins (CK) associated with different tissue types according to different
studies.  Results sited include Ogden et al (40), Sawaf et al (39), Morgan et al (41),
Vaidya et al (42), Xu et al (43), Cema et al (44), and Kannan et al (45).  An author’s
name in the + column indicates that the cytokeratin was associated with the tissue type by
their study.  An author’s name in the – column indicates that the cytokeratin showed
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19 Ogden Sawaf Morgan
Sawaf
Cema Xu Cema
As is evident in Table 2-3, there is no universal agreement as to the type of
cytokeratin associated with oral cancer, regardless of stage.  There are probably a number
of reasons for these conflicting results.  First, the tissue type will determine the
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cytokeratins expressed, and the oral cavity has numerous tissue types, including
cornifying stratified epithelia, noncornifying stratified epithelia, pseudostratified
columnar epithelia, junctional epithelia, and salivary glands (46).  In addition, the
location of the tissue within the oral cavity may affect cytokeratin expression.  Further,
the actual type of tumor will influence how the cytokeratin pattern changes with
tumorigenesis, with pre-neoplasia, squamous cell carcinoma, adenocarcinoma, and
odontogenic tumors showing differing expression patterns (46).  Finally, the different
antibodies used to probe the tissue and the various preparation techniques of the tissue
before histological examination by different researchers could affect the cytokeratins
detected.
It does appear, however, that cytokeratin 8 could be used in distinguishing
malignancy in the oral cavity, as it has been shown not to be present in normal tissue (40,
47) and has been associated with malignancy (39, 43, 47, 48).  Cytokeratin 18 could be
used in order to distinguish carcinoma from dysplasia and hyperplasia, as it has been
associated with all stages of carcinoma (39-42) and not with dysplasia or hyperplasia
(44).  However, the biggest challenge with using cytokeratins as a molecular marker for
living cells and tissue is that it is an intracellular target.  There is an inherent resistance to
transport of high molecular weight markers (49), and uptake relies on non-specific cell
endocytosis or permeablization of the cell membrane.
2.5.3 Other Molecular Markers of Oral Neoplasia
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Some molecular markers associated with oral cancer include p53, ras, myc, matrix
metalloproteinases (MMP), galectins, Ki-67, and the argyrophilic nucleolar organizer
region (AgNOR).  p53, ras, and myc are three examples of genetic markers which have
been associated with oral neoplasia.  p53 is a well-known tumor suppressor and in oral
cancer, p53 has been found to be mutated in up to 80% of cancers and the mutation may
occur before or during the transition period from precancer to SCC (12).  Further, the p53
gene is targeted either directly or indirectly by tobacco carcinogens (50).  Ras is a
potential oncogene whose protein product rasp21 is expressed in oral leukoplakias and
carcinomas but not in normal tissue (32).  Myc is another oncogene whose protein
product is increased in dysplasia and remained elevated throughout tumorigenesis (33).
p53, ras, and myc are only a small subset of genes implicated in the tumorigenic process
upon some form of mutation.
MMPs and galectins are two examples of extracellular and serum markers
associated with oral neoplasia.  MMPs appear to be important extrinsic regulators of
tissue remodeling that occurs when tumors acquire invasive characteristics (51).  MMP-1
expression increases during SCC progression and MMP-1 mRNA is detected in early
stages of SCC (52).  Further, MMPs are also required during angiogenesis, which is a
necessary step for continued tumor growth.  Aberrant expression of glycoproteins and
carbohydrate-binding molecules could affect interactions with the extracellular matrix
and basement membrane and may also occur in head and neck tumors (53, 54).  Galectin-
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1 and galectin-3 are expressed in head and neck squamous cell carcinoma lines and tumor
specimens and may play a role in cellular adhesion and recognition (53).
In addition to EGFR, Ki-67 and AgNOR are two examples of proliferative
markers.  In immunohistochemical analysis of oral cavity tissue, Ki-67-positive cells and
higher AgNOR numbers were found at the invasive tumor front (50).   An increase in
proliferative markers indicates an increase in cellular metabolic activity in the
tumorigenic progression.   
2.6 CONTRAST AGENTS
2.6.1 Endogenous Fluorescence
Tissue will autofluoresce due to endogenous fluorophores, including the reduced
form of nicotinamide adenine dinucleotide (NADH), flavins (FAD+, FMN, and
riboflavin), aromatic amino acids (tryptophan, tyrosine, and phenylalanine), collagen
crosslinks, and elastin crosslinks.  In addition, hemoglobin absorption also contributes to
fluorescence spectra by attenuating the excitation and emission wavelengths that overlap
with hemoglobin absorption, which is strongest at 420, 540, and 580 nm.  Changes in
tissue architecture and intrinsic fluorophores in malignant tissue from its normal
counterparts are reflected in their autofluorescence spectra.  These changes can be in
fluorophore concentration or spatial distribution, the metabolic status of a fluorophore,
the biochemical and biophysical microenvironment of the tissue, the tissue architecture,
or the distribution of non-fluorescent chromophores that attenuate light through
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absorption of the excitation or emission light (55).  Each of the intrinsic fluorophores has
a distinct excitation and emission spectra, as illustrated in Figure 2-5.
Figure 2-5  Fluorescence excitation (a) and emission (b) spectra of various endogenous
tissue fluorophores.  From (55).
However, the primary drawback to the use of autofluorescence is that the optical
excitation wavelengths are relatively short, limiting penetration depth into the tissue due
to increased scattering and absorption.  Therefore, deeper lesions cannot be easily
diagnosed.  Autofluorescence signals also tend to be relatively weak, photobleach
rapidly, and are subject to a low signal-to-noise ratio (SNR).  Finally, the exact nature of
the biological changes which drive the differences in fluorescence spectra between
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normal and abnormal tissue are not known.  The differences may be due to changes in
tissue architecture, such as thickening of the mucosa or loss of layered structure (55, 56),
and/or due to a combination of changes in both the concentration, form, and distribution
of endogenous fluorophores and the absorption properties of normal versus neoplastic
tissue (55, 57, 58).
The effectiveness of autofluorescence can be increased by the addition of 5-
aminolevulinic acid (ALA), which is a precursor to the endogenous fluorophore
protoporphyrin IX (PP IX) that accumulates in certain premalignant tissues (49, 59).
Exogneous addition of ALA bypasses the normal feedback control production of PP IX
(59), increasing the concentration of PP IX and leading to a better SNR.  In addition to
the tendency to accumulate PP IX and a higher rate than normal tissue, malignant cells
also convert ALA to PP IX at different rates and intensities than normal cells (59).  While
PP IX emits in the 600 nm range, it excites at 450 nm, so penetration depth is still limited
and absorption of hemoglobin could reduce the excitation efficiency of PP IX.  In
addition, Heintzelman et al found that while PP IX was associated with a larger number
of abnormal samples, it was not diagnostically useful for discriminating neoplastic tissue
in the oral cavity (58).
2.6.2 Dyes
In order to improve diagnostic accuracy and improve contrast, a number of
studies have been performed using vital dyes such as toluidine blue (molecular weight
305.83) and Lugol’s iodine solution (a solution of 5% iodine, molecular weight
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126.90447, and 10% potassium iodine, molecular weight 166.0 in water) as staining
agents.  These dyes are taken up by neoplastic tissue due to increased permeability of the
cell membrane.  However, tissue which has undergone trauma also displays increased
permeability and will show increased uptake of the dye relative to normal tissue even
though it has not undergone malignant transformation (49).  This contributes to the lack
of specificity associated with detection mediated solely by vital dyes.  A study which
determined the reliability of staining with toluidine blue in vivo to detect oral epithelial
dysplasia, in situ carcinoma, and squamous cell carcinoma associated with potentially
malignant epithelial lesions found a high sensitivity of 84% to 100% but a greatly
variable specificity of 44% to 100% (60).  Toluidine blue has been incorporated into a
commercially available ready-to-use kit (OraTest®, Zila Inc, Phoenix, AZ, known as
OraScan® in some countries) as a 1% toluidine blue solution for staining and a 1% acetic
acid solution for pre- and post-rinsing. As with toluidine blue studies, the OraScan® kit
showed a relatively high sensitivity of 79.5% but a low specificity of 62% (61). The low
specificity associated with toluidine blue staining is attributed to inflammation and
trauma areas which retained the stain (60), illustrating the major drawback to vital
staining.
Fluorescent molecules have also been used to detect tumors in vivo.  As with the
vital stains, the fluorescent molecules are not designed to be target-specific but show
increased uptake in tumor tissue as compared to normal tissue.  Aromatic lanthanide
chelates are examples of fluorescent molecules which have been used in rat models to
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detect colon cancer (49).  The near-infrared dye indocyanine green (ICG) has also been
used as a non-specific dye for in vivo imaging in cerebral pathways, mammary disease
and reactive lymph nodes, angiography in ophthalmology, hepatic function, and detection
of tumor margins in gliomas (49, 62-64).  The stability and intensity of ICG has also
shown to be increased by complexation to silver island films through human serum
albumin (63).
2.6.3 Target-specific Contrast Agents
Target-specific contrast agents have the advantage of increased molecular
specificity as compared to vital dyes.  Instead of simply relying on increased permeability
of the cell membranes of malignant tissue, target-specific contrast agents use molecular
markers which are associated specifically with neoplasia or are overexpressed in
neoplasia relative to normal tissue.  This has the potential to provide high detection
specificity due to enhanced accumulation of the contrast agent.  In addition, the use of
molecular markers that are expressed early in the transformation process could greatly aid
early detection.
The use of a fluorophore conjugated to a probe of the molecular marker would
further improve imaging by providing better optical properties and increased SNR
compared to autofluorescence.  By choosing a fluorophore with an excitation wavelength
above 600 nm, a high quantum yield, and a large Stokes shift, a target-specific contrast
agent can be designed with increased penetration depth into the tissue and a strong signal
that can be easily filtered from excitation light.  Probes that can be used in target-specific
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contrast agents include antibodies or antibody fragments against the molecular marker or
if the marker is a receptor, ligands for the receptor or short peptide sequences of the
ligand.  Contrast agents based on near infrared dyes conjugated to peptides for the
somatostatin receptor have been show to localize to tumors which overexpress the
receptor in vivo in rodent models (65, 66).  Localization to tumors in vivo in rodent
models has also been achieved by targeting the bombesin receptor (66) and the epidermal
growth factor receptor (37).  The cyanine family of dyes has been used as fluorescent
markers in target-specific contrast agents, using antibodies, antibody fragments, and
peptide platforms to localize to the tumor (49, 62, 67, 68).  Licha et al conjugated cyanine
dyes to somatostatin receptor-specific peptides and showed intracellular localization in
cell models (68).  Cyanine dyes with longer excitation and emission wavelengths were
shown to be more effective in visualizing tumors in deeper tissue than their shorter-
wavelength counterparts (62, 67).
A variation of target-specific contrast agents are those that are biologically
activated by proteases or reporter genes (49, 69).  These contrast agents are activated by
proteases, and generally contain fluorophores which are self-quenched until cleaved by
tumor-specific proteases.  This suppresses the fluorescent signal until it has localized to
the tumor, thereby amplifying the signal and SNR.  Weissleder et al bound near-infrared
fluorescence probes to a long circulating graft polymer, which quenched the signal until
cleavage by lysosomal proteases in tumor cells, and demonstrated a 12-fold increase in
signal between protease-activated and unactivated probes (69).   Reporter genes can also
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contain an optical signature, which can be used to monitor cellular events in vivo.  This
can be used to monitor tumor growth and progression and optimize treatment regimens
(49).
2.6.4 Quantum Dots
Quantum dots are seminconductor nanoparticles which are photochemically stable
with narrow, symmetric emission spectra and absorbance maxima that shift to higher
energy with decreasing particle size (70).  This results in tunable fluorophores that can be
excited at any wavelength shorter than the emission peak, but still emit the same
characteristic spectra regardless of excitation wavelength (70).  A spectral range from
400 nm to 2 µm with 20 to 30 nm FWHM can be achieved using various materials and
sizes for nanocrystals (70). The ability to excite multiple types of quantum dots with a
single excitation wavelength facilitates multi-color fluorescent labeling, which can be
used in biological systems to specifically label multiple targets simultaneously.  The
optical properties of quantum dots are potentially advantageous over traditional
fluorescent dyes, which require multiple excitation wavelengths, are more difficult to
resolve in multi-color labeling experiments, and tend to photobleach more quickly than
quantum dots.  The biggest challenge to using quantum dots in biological systems is their
lack of water solubility and potential toxicity.  This has been overcome by adding an
outer shell to the quantum dots, which makes them water-soluble without changing their
optical properties (70, 71).  In addition, this outer coating can be modified with various
chemical groups that allow covalent attachment to various biomolecules (70, 71) such
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that quantum dots can be used in place of fluorescent dyes in target-specific contrast
agents.  Silica-coated CdSe-CdS quantum dots have been used to specifically label actin
and nuclei of mouse 3T3 fibroblasts (70) while transport inside of HeLa cells was
demonstrated with zinc-capped CdSe quantum dots coated with mercaptoacetic acid
conjugated to transferrin (71).  These examples illustrate that quantum dots can be made
biocompatible and have the potential to be used in in vivo as part of target-specific
contrast agents.
2.7 OPTICAL DIAGNOSTIC TECHNIQUES OF ORAL NEOPLASIA
Optical techniques have the potential to provide near real-time diagnosis
information noninvasively.  In addition to greatly increasing patient comfort and reducing
loss to follow-up, cost-savings could also be realized by the medical industry by
eliminating unnecessary biopsies and reducing patient follow-up time (72).  Numerous in
vivo optical techniques have been developed including multi-spectral fluorescence
imaging, multi-spectral reflectance imaging with polarized and unpolarized light,
confocal microscopy (73, 74), reflectance spectroscopy with polarized and unpolarized
light (75, 76), and fluorescence spectroscopy (57).
2.7.1 Optical Spectroscopy
Optical spectroscopy techniques have the ability to provide quantitative
information of underlying biochemical and morphological changes that occur during
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tumorigenesis.  Because the information is quantitative, diagnosis becomes less
subjective and could potentially be performed by less specialized personnel.
As discussed previously, fluorescence spectroscopy can be used to distinguish
malignancy in the oral cavity based on autofluorescence.  A number of studies in in vitro
cell models, ex vivo tissue samples, and in vivo in patients have interrogated the ability to
use changes in autofluorescence as a distinguishing characteristic of neoplasia.
Sacks et al showed that the differentiation state of terminally differentiated cells
compared to less differentiated cells can be distinguished based on autofluorescence at
excitation wavelengths of 300 and 380 nm with emission at 450 and 510 nm respectively
(77).  In addition, Kolli et al determined the correlation between mean epithelial
thickness and changes in autofluorescence.  Comparing in vivo tumor sites to
contralateral normal sites, a correlation of 40% to the mean epithelial thickness of the site
was achieved using the ratio of fluorescence intensities at 290/330 nm in an excitation
scan from 200 to 360 nm measured at an emission wavelength of 380 nm and the ratio of
fluorescence intensities at 390/450 nm in an emission scan from 360 to 600 nm excited at
340 nm (78).  A correlation of only 40% between the fluorescence intensity ratios and the
mean epithelial thickness indicates that other factors are contributing to the observed
fluorescence (78).  Abnormal differentiation and epithelial thickening are hallmarks of
neoplasia, and these results suggest that autofluroescence can be used to distinguish
alterations in tissue which could be indicative of neoplasia.
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Studies investigating the changes in autofluorescence between normal and
abnormal tissue found that the differences in the fluorescence spectra can be used as
criteria to diagnose malignancy (55, 58, 79-81).  In the oral cavity, the optimal excitation
wavelengths for distinguishing oral neoplasia range from 300-400 nm (58, 81-85).
In a study using normal and cancerous ex vivo oral tissue samples, Wang et al
were able to use two excitation wavelengths to achieve a sensitivity of 81.25%,
specificity of 93.75%, and positive predictive value of 92.86% (56).  In this study, they
compared the performance of diagnostic classifications using single excitation
wavelengths by calculating the ratio of the area under the curve at emission wavelengths
of 330 +/- 5 nm and 470 +/- 5 nm (using excitation wavelengths of 280, 290, and 300
nm) and the ratio of the area under the curve at emission wavelengths of 380 +/- 5 nm
and 460 +/- 5 nm (using excitation wavelengths of 320, 330, and 340 nm) to the
performance of a classification scheme which paired the two ratios.  While the sensitivity
was the same for the single or two excitation wavelength classification, the two excitation
wavelength classification showed approximately a 30% increase in specificity and 20%
increase in positive predictive value compared to the single excitation wavelength
method.
In an in vivo study that consisted of a training set of 9 normal volunteers and 11
patients with suspected cancer and a validation set of 56 normal volunteers and 3 patients
with suspected cancer, Heintzelman et al were able to achieve 90% specificity and 90%
sensitivity in separating dysplasia and cancer from normal tissue using three excitation
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wavelengths (350, 380, and 400 nm) and an algorithm based on four emission intensities
(58).  When the algorithm was simplified to use a single emission wavelength at 472 nm
at all three excitation wavelengths, sensitivity remained at 90% and specificity dropped
only 2% to 88%.  They were further able to simplify their diagnostic algorithm using a
ratio of fluorescence intensities at two excitation wavelengths (400 and 350 nm) and at a
single emission wavelength (472 nm) and achieve an average sensitivity of 95 +/- 7% and
specificity of 93 +/- 6% for the training and validation sets.
In a 2000 review article on fluorescence spectroscopy, Ramanujam summarized
studies evaluating the performance of fluorescence spectroscopy for detecting invasive
carcinoma, early carcinoma, and dysplasia of the oral cavity (81).  Table 2-4 provides an
overview of spectroscopy studies based on autofluorescence.  Overall, the lowest
sensitivity achieved using fluorescence spectroscopy was 81.25% and the lowest
specificity was 87.5%.
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Table 2-4 Summary of results of studies reviewed by Ramanujam evaluating
fluorescence spectroscopy in the oral cavity for distinguishing carcinoma and dysplasia
from normal tissue.  The table includes the excitation and emission wavelengths used in
analysis, the sample size (normal N and abnormal A samples), and the resulting
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The performance of fluorescence spectroscopy can be further improved by
combining it with diffuse reflectance spectroscopy and light scattering spectroscopy in a
technique known as trimodal spectroscopy.  Each mode of spectroscopy provides
different information about the tissue; fluorescence spectroscopy provides direct
biochemical information, diffuse reflectance spectroscopy provides information on tissue
absorption and structure, and light scattering spectroscopy provides information on the
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size distribution of cell nuclei within the tissue (82).  In an in vivo study of 15 patients
with various degrees of malignancy and 8 normal volunteers, Müller et al were able to
achieve a sensitivity and specificity of 96%, a positive predictive value of 0.93, and
negative predictive value of 0.98 in distinguishing dysplasia and cancer from normal
tissue (82).  Further, they were able to achieve a sensitivity of 64%, specificity of 90%,
positive predictive value of 0.9, and negative predictive value of 0.64 in distinguishing
dysplasia from cancerous tissue.
2.7.2 Confocal Microscopy
In vivo imaging techniques, such as confocal microscopy, have the ability to
provide the intracellular detail used in histological analysis without removing or
physically sectioning the tissue (73).  Further, with the development of fiber-based
confocal microscopy (88-93), the possibility of imaging tissue in real time in vivo as a
means of diagnosis is a reality.
In a study of normal subjects comparing reflectance confocal images from the
tongue and lip to histology images, confocal images correlated well to histology both
qualitatively and quantitatively (74).  Clark et al were also able to use reflectance
confocal microscopy to image excised biopsies from the oral cavity and identify nuclear
and cellular changes characteristic of carcinoma (94).  In vivo confocal imaging of tooth
structure, cells of the gingival, and mucosal membrane as far back as the premolar teeth
has been performed by Watson et al (95).
36
2.8 PERMEABILITY-ENHANCING AGENTS
In order for exogenous contrast agents to be effective in vivo in targeting
neoplasia in tissue, it may be necessary to penetrate through multiple layers of epithelial
cells.  While contrast agents could be injected via i.v. or i.p. injection, topical application
would be preferable in order to minimize systemic exposure to the contrast agent.  In
addition, topical application is probably the most effective way to target an epithelial
cancer in the oral cavity.  However, in order to label deeper tumors, the contrast agent
will have to pass either intercellularly or intracellularly to reach cells near the basement
membrane or those which have invaded into the stroma, which may require that the
contrast agent be applied in conjunction with a permeability-enhancing agent.
Dimethyl sulfoxide (DMSO) is widely used in cell biology and medical
applications.  It has uses as a drug adjuvant, cryoprotective agent, free radical scavenger,
membrane fusogen, membrane permeabilizer, and inducer of cell differentation (96, 97).
DMSO itself is readily permeable through biological membranes, including human skin,
and can also enhance the permeability of low molecular weight solutes or increase their
penetration into the deeper layers of the skin (97).  The mechanism behind the ability
of DMSO to permeabilize biomembranes may be related to its ability to reduce the
distance separating lipid bilayers, allowing an increase in the flux of solutes across
lipid bilayers (96).  It may also reduce the energy required for a molecule to passively
diffuse across the cell membrane by removing the waters of hydration at the membrane
interface (96).
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Pyrroliodones are also known permeability enhancers (98).  By combining
polymers, which are often used in drug delivery, particularly for sustained release, with
pyrroliodones, drug permeation across a barrier can be improved, with
polyvinylpyrroliodone (PVP) being an effective combination (98).  4% bovine serum
albumin (BSA) has shown to improve recovery of lipophilic compounds across a cell
monolayer by reducing retention of the highly lipophilic compounds due to non-specific
binding and providing an absorptive driving force (99).
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Chapter 3
 A Far-Red Fluorescent Contrast Agent to Image Epidermal Growth
Factor Receptor Expression1
3.1 INTRODUCTION
Advances in optical technologies which offer novel noninvasive tools to improve
the screening and diagnosis of cancer and its precursors have recently generated much
excitement. These methods have the potential to provide diagnostic information in near
real-time without the need for biopsy and with minimal patient discomfort and cost.
Numerous optical techniques have been developed and tested in vivo in pilot studies,
including multi-spectral fluorescence imaging (100, 101), multi-spectral reflectance
imaging with polarized and unpolarized light (101, 102), confocal microscopy (73, 74),
reflectance spectroscopy with polarized and unpolarized light (75, 76, 103), and
fluorescence spectroscopy (55, 57, 81, 103).
The oral cavity is an ideal site for the application of optical techniques because of
accessibility and convenient visualization. Currently, diagnosis of oral cancer is achieved
through visual identification and recognition, which relies on the experience of the
treating clinician.  Optical techniques could potentially improve diagnosis and detection
                                                 
1 Portions of this chapter have been published previously in Hsu, E.R., E.V. Anslyn, S.
Dharmawardhane, R. Alizadeh-Naderi, J.S. Aaron, K.V. Sokolov, A.K. El-Naggar, A.M.
Gillenwater, and R.R. Richards-Kortum, 2004.  A far-red fluorescent contrast agent to
image epidermal growth factor receptor expression.  Photochem. Photobiol. 79(3), 272-
279.
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of oral cancer by allowing objective assessment of the molecular and biochemical
changes in neoplastic tissue relative to normal tissue.  Successful application and
validation of these techniques will lead to better screening and early detection of
premalignant lesions, reducing incidence of cancer in high-risk individuals.
 Recently, in vivo studies have demonstrated the ability of fluorescence
spectroscopy to distinguish neoplasia in the oral cavity based on autofluorescence.
Excitation wavelengths optimal for diagnosis of invasive carcinoma, early carcinoma,
and dysplasia lie within the range of 300-440 nm (58, 81-85).  While preliminary results
with autofluorescence are promising, there are several limitations.  First,
autofluorescence signals tend to be relatively weak, photobleach rapidly, and are subject
to low signal-to-noise ratio (SNR).  Second, the penetration depth of the near UV and
blue excitation wavelengths are relatively limited, implying that deeper lesions or deeper
margins of superficial tumors cannot be easily evaluated.
Molecular-specific, exogenous optically active contrast agents that bind to
biomarkers modified early during neoplastic transformation may facilitate the detection
of early neoplastic lesions (16) and improve diagnostic accuracy and contrast.  The use of
a highly stable, high quantum yield fluorophore conjugated to a molecular-specific probe
of the biomarker would also allow increased SNR compared to autofluorescence.  In
addition, using an exogenous fluorophore with excitation and emission wavelengths in
the red to near infrared region increases the penetration depth.
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  Several studies have shown overexpression of epidermal growth factor receptor
(EGFR) in premalignant and invasive oral squamous epithelial lesions. EGFR expression
is detected at all stages of carcinogenesis, from normal-early hyperplasia, dysplasia, and
invasive carcinoma (32, 33).  EGFR expression is elevated during the progression from
hyperplasia to dysplasia and increases during progression from dysplasia to invasive
squamous cell carcinoma (SCC) (34).  Moreover, EGFR expression is elevated in normal
epithelium which is adjacent to tumor (34), regardless of tobacco and alcohol abuse (35).
Nouri et al found that 73% of the invasive oral SCC they studied showed strong
expression of EGFR (23).  Other reports have estimated overexpression of EGFR in all
oral cancers at 50-98% (21).
Soukos et al targeted SCC by conjugating an EGFR antibody to a photoactive
molecule and demonstrated regression of premalignant lesions in the Syrian golden
hamster cheek model after i.v. injection of the conjugate and exposure to therapeutic
doses of light (37).  In addition, they were able to visualize dysplasia in their model using
a conjugate of the antibody and a fluorescent dye three days after i.v. injection of the
antibody-dye conjugate.  However, for diagnostic purposes, topical application of the
contrast agent would be preferable in order to minimize patient discomfort, systemic
exposure to the contrast agent, and possible immunogenic effects.
The purpose of the present study is to develop and evaluate a molecular-specific
contrast agent to EGFR using a monoclonal antibody and far-red fluorescent dye which
could be applied topically for detection of oral cavity neoplasia in humans.  The first
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steps in the development of a contrast agent for potential use in in vivo detection of oral
cancer are to test the efficacy of the contrast agent in in vitro and ex vivo models.  In this
study, we demonstrate the specificity of the agent for imaging EGFR in cancer cell lines
and the ability to penetrate throughout 500 µm thick multilayer epithelial tissue
constructs when applied topically with permeability-enhancing agents such as dimethyl
sulfoxide (DMSO), polyvinylpyrrolidone (PVP), and bovine serum albumin (BSA).  In
order to test the penetration depth of the contrast agents across multiple layers of
epithelial cells, mutilayer tissue constructs which have been shown to mimic the optical
properties of the epithelial layer in vivo were used (104). Finally, we demonstrate the
potential use of the fluorescence intensity of the contrast agent to distinguish abnormal
tissue from normal tissue using fresh tissue slices prepared from biopsy samples from the
oral cavity.  We conclude that this contrast agent could potentially be used in conjunction
with fluorescence spectroscopy and/or imaging to improve quantitative, objective tumor
detection and demarcation.
3.2 MATERIALS AND METHODS
3.2.1 Contrast Agent
The antibody used in the contrast agent was a biotinylated mouse monoclonal
anti-human EGFR (clone 111.6, 200 mg/ml, LabVision NeoMarkers, Fremont, CA) and
was used at a 1:10 dilution.  The antibody is targeted against the extracellular domain of
EGFR and blocks the binding of epidermal growth factor (EGF) to the receptor.  Alexa
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Fluor® 660 streptavidin (Molecular Probes, Eugene, OR) was used as the far-red
fluorescent marker.  Alexa Fluor® 660 streptavidin has a broad absorption peak with a
maximum at 669 nm, but can also be excited at 633 nm or 647 nm.  Its emission
maximum is at 690 nm with a relative quantum yield of 0.88 compared to 7-hydroxy-9H-
(1, 3-dichloro-9, 9-dimethylacridin-2-one) (DDAO).  Alexa Fluor® 660 streptavidin has
a degree of labeling of 4.7 moles of dye per mole of protein using an e of 110,000 cm-1
M-1 at the absorbance maximum (all information on Alexa Fluor® 660 streptavidin as
reported by Molecular Probes in the Certificate of Analysis for lot #65C1). The dye was
provided as a 1 mg lyophilized powder and reconstituted in 1 ml of deionized water and
stored in frozen aliquots.  For use in labeling, it was diluted to 250 mg/ml in PBS and
used at a 1:8 dilution.
3.2.2 Cell Lines
Six human cell lines were tested: MDA-MB-468 (American Type Culture
Collection, Manassas, VA), an adenocarcinoma of the mammary gland known to
overexpress EGFR at ~1x106 receptors/cell (receptor number/cell from American Type
Culture Collection and (105)), MDA-MB-435S (American Type Culture Collection), a
ductal adenocarcinoma of the breast which expresses no EGFR (105), SiHa (American
Type Culture Collection), a squamous cell carcinoma of the cervix, SqCC/Y1 (kindly
provided by Reuben Lotan, at the University of Texas M.D. Anderson Cancer Center), a
squamous cell carcinoma of the buccal mucosa, UMSCC-22A (kindly provided by
Reuben Lotan), derived from a primary tumor of the hypopharynx, and A253 (American
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Type Culture Collection), an epidermoid carcinoma of the submaxillary salivary gland .
MDA-MB-468 and MDA-MB-435S cells were grown in minimal essential media
(Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT),
penicillin, streptomycin, glutamine, sodium pyruvate, non-essential amino acids, and
vitamins (Invitrogen).  SiHa, SqCC/Y1, and UMSCC-22A cells were grown in
Dulbecco’s modified essential media/F12 (Invitrogen) with 5% FBS, penicillin,
streptomycin, and glutamine.  A253 cells were grown in McCoy’s 5A (Invitrogen) with
5% FBS, penicillin, streptomycin, and glutamine.  To grow monolayers of cells for
imaging, small wells were created using adhesive CoverWell imaging chambers (Grace
Bio-Labs, Bend, OR) with a 25 mm diameter and 0.5 mm depth secured to a No. 1 24x40
mm glass coverslip.  Cells were plated at a density of 0.2 million cells/ml in the
chambers, and allowed to grow for 3-4 days in a 37oC incubator with 5% CO2 until 60-
90% confluency.
3.2.3 Multilayer Tissue Constructs
Multilayer tissue constructs representing the structure of oral dysplasia were
created using SqCC/Y1 cells. A collagen solution was prepared by combining collagen
(Roche Applied Science, Indianapolis, IN) reconstituted in 0.2% sterile acetic acid, 0.2 M
HEPES, 10x phosphate buffered saline (PBS), and 1x PBS, final pH 7.4.  SqCC/Y1 cells
were resuspended in the collagen solution at a density of 80 million cells/ml.  Tissue
constructs were formed by pipetting 100 µl of the cell-collagen solution into Costar
Transwell inserts (VWR, West Chester, PA), 6.5 mm diameter with an 8 µm pore size,
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allowing the tissue constructs to gel, and adding media in the insert on top of the tissue
construct and to the bottom well.  PBS was added to empty wells to increase humidity
within the plate.  The tissue constructs were allowed to grow for 14-21 hours in a 37oC
incubator with 5% CO2.
3.2.4 Cell Monolayer Labeling
Three samples were prepared: cells labeled for EGFR using the biotinylated
EGFR antibody and two sets of control cells, one labeled using a biotinylated anti-human
IgG (goat monoclonal, Vector Laboratories, Burlinghame, CA) and one not exposed to
any antibody but labeled with the Alexa Fluor® 660 streptavidin dye only.  Between all
changes of solution, cells were washed 2x with 1x PBS.  The media was removed from
the wells and cells were blocked for endogenous biotin using an Avidin/Biotin blocking
kit (Vector Laboratories).  Cells were successively incubated with the primary EGFR or
IgG antibody and the Alexa Fluor ® 660 streptavidin for 1 hour at room temperature.
After the final washes, PBS was added to the chambers and sealed using a microscope
slide.
3.2.5 Multilayer Tissue Constructs Labeling
Multilayer tissue constructs were labeled in a similar fashion to the cells with
either the EGFR antibody or anti-human IgG antibody.  In addition, the blocking agents,
antibodies, and dye were added in permeability-enhancing solutions of 5% DMSO, 10%
PVP, or 4% BSA in addition to a PBS control.  After labeling in the Transwells, the
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tissue constructs were removed, embedded in 3% agarose, and sliced transversely into
250 mm sections using a Krumdieck tissue slicer (MD 1000-A1, Alabama Research and
Development, Munford, AL) which is designed to cut fresh tissue with minimal damage.
Three replicates of each experiment were performed.
3.2.6 Fresh Tissue Slices
Paired clinically abnormal and clinically normal biopsies were obtained from
consenting patients at the University of Texas M.D. Anderson Cancer Center.  The
clinical protocols were approved by the Institutional Review Boards at the University of
Texas M.D. Anderson Cancer Center and the University of Texas at Austin.  Biopsies
were immediately placed and remained in chilled culture media until they were sectioned
into 200 µm transverse slices using a Krumdieck tissue slicer.  After slicing, biopsies
were labeled as above.  The avidin and biotin blocking solutions were added in a 5%
BSA solution in PBS.  A biotinylated normal mouse IgG (Vector Laboratories) was used
as a control.   H&E stained sections were obtained for each biopsy and the slices that
were labeled for EGFR and imaged.
3.2.7 Imaging
Optically sectioned fluorescence images of the samples were obtained using an
inverted Lecia TCS 4D laser scanning confocal microscope, equipped with a Kr/Ar laser
providing excitation at 647 nm and a 665 nm long-pass filter.  Images were acquired with
a 10x objective with a numerical aperture of 0.3 and working distance of 11000 µm or
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40x oil-immersion objective with a numerical aperture of 1.0 and working distance of 80
µm.  The laser power for image acquisition varied between 3-30 µW.  Stacks of images
were obtained, with a z-step of 1.5-3 µm and 5-30 images per stack.  The contrast,
brightness, line averaging, integration time, and pinhole size remained constant for all
images in a single experiment.
3.2.8 Fluorometry
Fluorometry was used in order to determine the efficacy of binding using various
primary antibody concentrations, incubation times, and the specificity of binding of the
contrast agent.  Fluorescence emission spectra of suspensions of SqCC/Y1 cells labeled
for EGFR were measured in a Spex Fluorolog (JY Horiba, Edison, NJ).  Approximately
8-9 million cells were harvested for each sample and resuspended in phenol red-free
DMEM with 5% FBS, penicillin, streptomycin, and glutamine.  Labeling was performed
as for cell monolayers, with the cells centrifuged at 1000 rpm for 3 min in order to
change solutions and wash.  After labeling, the cells were washed in PBS and
resuspended in 3 ml of PBS for the emission scans.  Fluorescence emission spectra were
measured at an excitation wavelength of 633 nm and emission wavelengths from 643-700
nm at 5 nm increments with a 1 s integration time.  Background fluorescence emission
spectra were determined by pelleting the cells and measuring the supernatants of the cell
suspensions.  PBS was also measured as a background.  The fluorescence intensity was
determined by calculating the area under the emission curve after subtracting the
background PBS and/or supernatant.
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In order to test the efficacy of labeling at various antibody concentrations and
incubation times, cells were labeled using various dilutions of biotinylated EGFR
antibody and biotinylated normal mouse IgG of 1:4, 1:10, 1:50, and 1:100 with a 60 min
incubation time and using various incubation times of 5, 15, 30, and 60 minutes with a
1:10 antibody dilution.
The specificity of the contrast agent for EGFR was tested in a competitive binding
study with EGF.  Lyophilized EGF (Sigma Aldrich, St. Louis, MO) was reconstituted in
0.2 µm-filtered 10 mM acetic acid with 0.1% BSA.  Cells were labeled as above, with
either no, 0.0133 µM, 0.133 µM, or 1.33 µM EGF added in addition to the anti-EGFR
antibody.
3.2.9 Quantitative Flow Cytometry
Quantitative flow cytometry was performed on the SqCC/Y1 to determine how
many receptors per cell were being labeled.  Standard beads from a QIFI kit (Dako
Cytomation, Carpinteia, CA) with known amounts of mouse monoclonal anti-CD5
immobilized on the surface produced a calibration curve from which the number of
labeled receptors on the cells could be interpolated.  Cells were harvested at 70%
confluency or less and resuspended at a concentration of 1 million cells/ml in 1 ml of
PBS with 5% BSA.  Cells were labeled for EGFR using the unbiotinylated version of the
same EGFR antibody used in the contrast agent at a 1:10 dilution in phenol red-free
DMEM with 5% FBS, penicillin, streptomycin, and glutamine for 1 hour at room
temperature with constant shaking.  A secondary antibody of goat anti-mouse F(ab’)2-
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FITC (Dako Cytomation) at a concentration of 1 mg/ml was added at a 1:10 dilution to
detect the EGFR antibody.  Three control samples were also prepared: cells labeled with
normal mouse IgG (Vector Laboratories), cells labeled with the secondary antibody only,
and unlabeled cells.  MDA-MB-468 cells were also labeled for EGFR as a positive
control.  In addition, a second quantitative flow cytometry experiment was performed
using SqCC/Y1, UMSCC-22A, and A253 cells. Quantitative flow cytometry was
performed on a Coulter EPICS Elite flow cytometer with a 15 mW argon laser source at
488 nm.
3.3 RESULTS
To determine the efficacy of using a molecular-specific far-red fluorescent
contrast agent to EGFR to detect oral cavity neoplasia, we labeled unfixed monolayers of
malignant cells, multilayer tissue constructs, and fresh tissue sections from oral cavity
biopsies.
3.3.1 Detection of EGFR in Single Cell Monolayers
Fluorescence images of SqCC/Y1 cells labeled with biotinylated anti-EGFR
conjugated to Alexa Fluor® 660 streptavidin obtained with a 40x objective are shown in
Fig. 1 along with images of appropriate controls and images of MDA-MB-435S cells.
Clear fluorescence is seen for SqCC/Y1 cells labeled with the anti-EGFR in Figure 3-1
(a) with the corresponding transmitted DIC image in Figure 3-1 (b).  No fluorescence is
seen with either the anti-IgG (Figure 3-1 (c) and (d)) or dye-only control (Figure 3-1 (e)
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and (f)).  Similar results are seen for MDA-MB-468, SiHa, UMSCC-22A, and A253 cells
with the MDA-MB-468 cells showing a much greater fluorescence intensity than the
SqCC/Y1 cells (images not shown).  MDA-MB-435S cells, which do not express EGFR,
show very little fluorescence when labeled with the anti-EGFR (Figure 3-1 (g)).
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Figure 3-1 Confocal images of SqCC/Y1 and MDA-MB-435S cells taken with a 40x oil






excitation 647 nm with a 665 nm longpass filter.  (b), (d), (f), and (h) are transmitted DIC
images.  Scale bar in all images is 25µm. (a) SqCC/Y1 cells labeled with anti-EGFR and
Alexa Fluor® 660 streptavidin.  (b) Corresponding transmitted DIC image.  (c) SqCC/Y1
cells labeled with anti-human IgG and Alexa Fluor® 660 streptavidin.  (d) Corresponding
transmitted DIC image.  (e) SqCC/Y1 cells labeled with Alexa Fluor® 660 streptavidin
only, no antibody.  (f) Corresponding transmitted DIC image.  (g) MDA-MB-435S cells
labeled with anti-EGFR and Alexa Fluor® 660 streptavidin.  (h) Corresponding
transmitted DIC image.
3.3.2 Detection of EGFR in Multilayer Tissue Constructs
Fluorescence images of SqCC/Y1 tissue constructs obtained with a 10x objective
are shown in Fig. 2.  Tissue constructs labeled in the presence of 5% DMSO Figure 3-2
(b)), 10% PVP (Fig. 2 (c)), and 4% BSA (Fig. 2 (d)) demonstrate labeling through a
greater depth than those labeled in PBS only Figure 3-2 (a)). For the corresponding anti-
human IgG controls of the tissue constructs, some non-specific labeling is seen with 10%
PVP (Figure 3-3 (a)) and 4% BSA (Figure 3-3 (b)).  The image shown in Figure 3-3 (b)
for the 4% BSA IgG control showed the most fluorescence of all 3 trials, but it appears
the labeling is non-specific when compared to the contrast agent in Figure 3-2 (d) where
individual cells can be clearly seen. The 10% PVP IgG control shown in Figure 3-3 (a)
has a relative fluorescence intensity less than with the contrast agent shown in Figure 3-2
(c).  Fluorescence images of the same tissue constructs labeled in the presence of PBS
and 5% DMSO obtained with a 40x objective are shown in Figure 3-4.  Cell membrane
EGFR labeling of cells embedded in collagen is clearly evident in both cases, though
labeling is more intense in the presence of 5% DMSO (Figure 3-4 (c)).
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Figure 3-2 False color confocal images of SqCC/Y1 tissue constructs labeled with anti-
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agents taken with a 10x objective.  The scale bar in all images is 100 µm.  (2) images are
the top of the constructs with the contrast agent applied from the right.  (1) images are the
bottom of the tissue construct, with the line representing the approximate location of the
bottom of the construct.  (a) Tissue constructs labeled in the presence of PBS only.  (b)
Tissue constructs labeled in the presence of 5% DMSO.  (c) Tissue constructs labeled in
the presence of 10% PVP.  (d) Tissue constructs labeled in the presence of 4% BSA.
Figure 3-3 False color confocal images of SqCC/Y1 tissue constructs labeled with anti-
human IgG and Alexa Fluor® 660 streptavidin in the presence of permeability-enhancing
agents taken with a 10x objective.  The scale bar in both images is 100 µm.  (a) Tissue
construct labeled in the presence of 10% PVP.  (b) Tissue construct labeled in the
presence of 4% BSA.
a b
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Figure 3-4 Confocal images of SqCC/Y1 tissue constructs labeled with anti-EGFR and
Alexa Fluor® 660 streptavidin taken with a 40x oil immersion objective.  (a) and (c) are
false color fluorescence images obtained at excitation 647 nm with a 665 nm longpass
filter.  (b) and (d) are transmitted DIC images.  Scale bar in all images is 25µm.  (a) and
(b) Tissue constructs labeled in the presence of PBS only.  (c) and (d) Tissue constructs
labeled in the presence of 5% DMSO.
3.3.3 Detection of EGFR in Fresh Tissue Slices
Fluorescence images from a clinically abnormal and clinically normal biopsy pair
are shown in Figure 3-5 (a) and (b), labeled for EGFR using the contrast agent obtained
with a 40x objective.  Figure 3-5 (c) and (d) show the corresponding H&E images for the




obtained from the retromolar trigone and diagnosed as moderate dysplasia of the
squamous epithelium with underlying foci of invasive squamous carcinoma.  The normal
biopsy was obtained from the pharyngeal wall and diagnosed as normal with mild
hyperkeratosis.  The fluorescence intensity is considerably higher in the abnormal sample
(Figure 3-5 (a)) than in the normal sample (Figure 3-5 (b)), by an average factor of 5x.
Figure 3-5 Confocal images of tissue slices from a (a) clinically abnormal and (b)
clinically normal biopsy pair and corresponding H&E images ((c) and (d) respectively).
Confocal images taken with a 40x oil immersion objective; scale bar is 25 µm.  H&E
images taken with a 10x objective.    Abnormal biopsy taken from the retromolar trigone.
Diagnosis of (c) was moderate dysplasia in the epithelium with  foci of moderately-
differentiated cancer.  Normal biopsy taken from the pharyngeal wall.  Diagnosis of (d)




3.3.4 Fluorometry of Cells Labeled for EGFR
The mean fluorescence intensities of SqCC/Y1 cells labeled for various
incubation times and with various dilutions of EGFR antibody are shown in Fig. 6.  In
Fig. 6, the squares are cells labeled for EGFR corrected for background intensity by
subtracting IgG and the diamonds are cells labeled using the IgG control.  Cells labeled
for various incubation times of 5, 15, 30, and 60 min showed a linear increase in
fluorescence with increasing incubation time as shown in Figure 3-6 (a).   Cells labeled
using various dilutions of the EGFR antibody of 1:4, 1:10, 1:50, and 1:100 also showed a
linear increase in fluorescence with increasing antibody concentration as shown in Figure
3-6 (b).  In both cases, the shortest incubation time and the lowest antibody dilution still
demonstrated a significant increase in fluorescence compared to the control.  Cells
labeled in the presence of 0.0133 µM EGF did not show a significant difference in
fluorescence intensity compared to those labeled in the presence of no EGF.  However,
the cells labeled in the presence of increasing concentrations of EGF showed a linear


















































































Figure 3-6 (a) Fluorescence intensities for SqCC/Y1 cells labeled for various incubation
times using a 1:10 antibody dilution averaged over three trials.  (b) Fluorescence
intensities for SqCC/Y1 cells labeled with different dilutions of antibody using a 60 min
incubation time averaged over three trials.  In both graphs, the PBS background and
background produced by the supernatant of the cell suspension has been corrected for in
all samples.  The squares are cells labeled using EGFR, corrected for the background









































Figure 3-7 Fluorescence intensities for SqCC/Y1 cells labeled with the contrast agent in
the presence of no EGF, 0.0133 µM EGF, 0.133 µM EGF, and 1.33 µM EGF averaged
over three trials.  All samples are corrected for the PBS background and background
produced by the supernatant of the cell suspension.
3.3.5 Quantitative Flow Cytometry
The number of EGFR per cell was determined for SqCC/Y1 cells using the QIFI
kit analysis.  Approximately 300,000 receptors per cell were labeled in the first
experiment (data not shown).  Other investigators reported the number of EGF receptors
per cell as 4.70-8 x 105 (26, 106), similar to that reported here.
The second quantitative flow cytometry experiment using the three cell lines from
the oral cavity demonstrated that labeling could be achieved on cell lines with various
levels of EGFR expression.
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The standard curve generated by the QIFI calibration beads is illustrated in Figure
3-8, with the mean fluorescence intensity from each of the cell lines plotted along the
standard curve.  The number of EGFR per SqCC/Y1 cell from this experiment was
approximately 200,000, slightly less than in the first experiment.  A253 cells were
calculated to have approximately 100,000 EGFR per cell, which agrees with reported
literature of 0.51x105 and 1.15x105 low and high affinity EGFR binding sites per cell
(26).  The UMSCC-22A cells were determined to have an intermediate number of EGFR

































Figure 3-8 Standard curve generated by quantitative flow cytometry data, plotting the
number of monoclonal antibody immobilized on the bead versus the mean fluorescence
intensity determined by flow cytometry (black diamonds).  The mean fluorescence
intensity for each of the cells lines, SqCC/Y1 (pink square), UMSCC-22A (yellow
triangle), and A253 (blue circle) is plotted along the standard curve, and the number of
EGFR/cell interpolated from the standard curve.
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3.4 DISCUSSION
In vitro experiments with cell cultures demonstrate that the contrast agent
specifically targets the extracellular membrane of neoplastic cells and suggests specific
targeting of EGFR.  EGFR is a transmembrane protein, thus as expected, fluorescence is
seen primarily at the cell membrane, where the EGF receptor is located, and little to no
fluorescence is seen with controls.  The fluorometry competitive binding studies with
EGF demonstrate the contrast agent binds to a much lower degree in the presence of
EGF, also suggesting that it is specifically targeting EGFR.
An advantage of using Alexa Fluor® 660 streptavidin is that it has a broad
absorption peak, allowing it to be efficiently excited between 633-660 nm with emission
at 690 nm.  The broad excitation range allows the contrast agent to be used readily with
the 633 nm laser line of a HeNe or the 647 nm laser line of a krypton-ion laser while still
maintaining a relatively long Stokes shift for easy rejection of elastically scattered
excitation.  An excitation wavelength greater than about 600 nm allows for increased
penetration depth into tissue with substantially reduced interference from autofluoresence
of endogenous fluorophores and scattering and absorption from tissue structures.
Fluormetry experiments with varying dilutions of the EGFR antibody and varying
the incubation time indicate that the antibody can be used in relatively low concentrations
and only short incubation times are required to achieve a detectable fluorescence signal.
The use of low antibody concentrations is critical in the development of the contrast
agent to minimize the possibility for immunogenic effects and to keep costs low.  In
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addition, for clinical applications of the contrast agent, a short incubation time is critical
in order to achieve expedient diagnosis with minimal patient discomfort and waiting
time.
Numerous studies have achieved localization of target-specific NIR fluorescent
contrast agents to tumors using monoclonal antibodies or peptide delivery platforms in
vivo in animal models (37, 62, 65-67), however in all cases, the conjugate was delivered
via i.v. or i.p. injection.  In contrast, we are exploring methods to achieve labeling
through topical application of the contrast agent.  Topical application of the contrast
agent is ideal to reduce systemic exposure to the contrast agent and minimize the
discomfort associated with i.v. injection.  However, in order to label deeper lesions
through topical application, the contrast agent may have to be applied in conjunction with
permeability-enhancing agents in order to increase the penetration depth through multiple
layers of epithelial cells.  DMSO, PVP, and BSA have all been applied as penetration
enhancers across biomembranes, cell monolayers, and multiple layers of epithelial cells
(96-99, 107).  All three permeability-enhancing agents tested here, 5% DMSO, 10%
PVP, and 4% BSA, increased penetration of the contrast agent relative to PBS in tissue
constructs.  Tissue constructs labeled in the presence of either DMSO or PVP
demonstrated fluorescence to the bottom of the tissue construct, approximately 500 µm.
The ability to distinguish abnormal from normal tissue based on fluorescence
intensity of the contrast agent was achieved.  In the biopsy pair presented here, the
dysplastic slice had a fluorescence intensity 5x greater than that of the normal slice.
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Histologically, the abnormal slice contained both dysplasia in the epithelium and foci of
moderately-differentiated cancer while the normal slice was normal with mild
hyperkeratosis.  Although EGFR is expressed in normal tissue, the likelihood is that
overexpression of EGFR in abnormal tissue provides sufficiently increased fluorescence
intensity to discriminate abnormal from normal tissue.  In addition, while the elevation of
EGFR in normal-early hyperplasia and in normal tissue adjacent to tumor may lead to
false positive diagnoses, it also has the possibility to facilitate early detection by
providing a marker for tissue which is likely to undergo carcinogenesis and should be
monitored.  A preliminary clinical study testing at least 20 pairs of abnormal and normal
biopsies from the oral cavity is currently in progress to determine the efficacy of
distinguishing abnormal from normal tissue based on the fluorescence intensity of the
contrast agent.
Fluorescence spectroscopy and/or imaging could be used in order to detect the
signal of the contrast agent in vivo and localize potential tumors or tumor margins.  In
addition, with the development of fiber-based in vivo confocal microscopes (88-93),
including the commercially available fiber-based confocal fluorescence microscopes
produced by OptiScan Imaging Limited (Victoria, Australia) and Mauna Kea
Technologies (Paris, France), the contrast agent could be used to provide additional
signal for imaging applications to the epithelial layer in vivo to allow for diagnosis of
abnormal tissue.
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 A number of significant issues must be addressed prior to performing clinical
trials with this contrast agent.  Issues which must be considered are toxicity of the Alexa
Fluor® 660 dye, possible immunogenic effects of the antibody, optimal time for
localization of the contrast agent to neoplasia and subsequent imaging, and clearance of
the contrast agent from the tissues.  While these pharmokinetic issues will need to be
addressed, we have demonstrated that the contrast agent has the ability to target EGFR-
positive cells in viable in vitro biological models of cell monolayers and cell suspensions,
that deeper labeling is possible through topical application and the use of permeability-
enhancing agents, and that there is the potential to distinguish abnormal from normal
tissue based on fluorescence intensity in ex vivo biopsy samples.
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Chapter 4
Detection of Epidermal Growth Factor Receptor Expression in Ex Vivo
Oral Cavity Biopsies Using a Molecular-Specific Contrast Agent
4.1 INTRODUCTION
Over the past 40 years, the five-year survival rate for oral cancer has not
significantly increased although treatment techniques have advanced (7, 8).  This is most
likely due to the fact that oral cancer is generally not diagnosed until it has reached later
stages, when treatment is more debilitating and prognosis is poor.  Failure to recognize
oral cancer in its early stages is primarily because detection of oral cancer relies entirely
upon recognition and suspicion by the treating clinician.  The oral cavity is tended to by
two different types of clinicians and this split in professional responsibility may lead to a
deficiency in the recognition of suspicious lesions and diagnosis of disease (13).  The
dentist, who is most familiar with this anatomical region, most often treats the oral cavity,
but may not have specialized training in recognizing early cancer.  This may result in a
lack of diagnosis until a lesion has reached advanced stages when it is easily identifiable
as cancer.
Detection of early cancer in the oral cavity could be greatly improved through the
use of molecular markers that are indicative of the transformation process.  Molecular
markers can act as early indicators of disease or progression of disease (16), and possibly
permit detection of cancer before a clinician would recognize the lesion.   One method of
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utilizing molecular markers as an indicator of disease is to develop fluorescent contrast
agents which specifically target the molecular marker and can be interrogated in vivo
using optical techniques such as spectroscopy or confocal microscopy.  Optical
techniques have the advantage of the potential to provide near real-time information non-
invasively, while most current diagnostic methods in the oral cavity require biopsy and
microscopic examination of tissue.
Epidermal growth factor receptor (EGFR) is a promising molecular target for
detection of oral cancer because various studies have estimated that 50-98% of tumors in
the oral cavity overexpress EGFR (27-31).  EGFR is expressed in normal tissue in cells
that are undergoing proliferation (24), with elevated expression during the progression to
dysplasia and cancer (34).  Researchers have also investigated the correlation between
EGFR expression and tumor staging, prognosis, and relapse.  Studies have found that
tumor EGFR levels are correlated to the size of tumor (30, 31) and that mean values of
EGFR increase with tumor size and advanced clinical stage (28).  In a correlative study of
patients with advanced head and neck squamous cell carcinoma (HNSCC) enrolled in a
radiotherapy study, EGFR expression was a strong prognostic indicator for overall
survival and disease-free survival and was highly predictive for the probability of local-
regional relapse but not distant metastasis (36).  Other studies, however, have reported no
significant correlation between EGFR levels and tumor staging (27, 28, 36).
Previously, we demonstrated the efficacy of a far-red fluorescence contrast agent
targeted against EGFR in squamous carcinoma cells of the buccal mucosa in monolayer
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culture and in 500 µm thick multilayer tissue constructs (108).  In this study, we are
further exploring the use of the contrast agent by testing it in ex vivo paired normal and
abnormal biopsy samples obtained from consenting patients at the University of Texas
M.D. Anderson Cancer Center.
4.2 MATERIALS AND METHODS
4.2.1 Contrast Agent
The contrast agent is described in detail in (108), but will be briefly reviewed
here.  The antibody used in the contrast agent was a biotinylated mouse monoclonal anti-
human EGFR (clone 111.6, 200 mg/ml, LabVision NeoMarkers, Fremont, CA) and was
used at a 1:10 dilution.  Alexa Fluor® 660 streptavidin (Molecular Probes, Eugene, OR)
was used as the far-red fluorescent marker.  For use in labeling, it was diluted from a 1
mg/ml stock to 250 mg/ml in PBS and used at a 1:8 dilution.
4.2.2 Fresh Tissue Slices
Paired clinically abnormal and clinically normal biopsies were obtained from
consenting patients at the University of Texas M.D. Anderson Cancer Center.  The
clinical protocols were approved by the Institutional Review Boards at the University of
Texas M.D. Anderson Cancer Center and the University of Texas at Austin.  Biopsies
were immediately placed and remained in chilled culture media (phenol-red free,
Dulbecco’s modified essential media/F12 with high glucose, Invitrogen, Carlsbad, CA)
until they were sectioned into 200-400 µm transverse slices using a Krumdieck tissue
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slicer (MD 1000-A1, Alabama Research and Development, Munford, AL) which is
designed to cut fresh tissue with minimal damage.  After slicing, biopsies were labeled
using the contrast agent.  The tissue slices were first blocked for endogenous biotin using
an Avidin/Biotin blocking kit (Vector Laboratories, Burlinghame, CA) in a 5% bovine
serum albumin (BSA) solution in PBS.  The tissue slices were successively incubated
with the primary EGFR antibody or a biotinylated normal mouse IgG (Vector
Laboratories) and the Alexa Fluor® 660 streptavidin for 30 min. at room temperature
with constant shaking.   All dilutions were prepared in a 1.25% BSA solution in PBS.
Between all changes of solution, the tissue slices were washed in PBS for 5 min. two
times with constant shaking. Hematoxylin and eosin (H&E) stained sections and EGFR
immunohistochemistry (IHC) was obtained for each biopsy and the slices that were
labeled for EGFR and imaged.  H&E stained sections were examined by a board-certified
pathologist and diagnosis was assessed using standard histopathological criteria as
follows: normal, hyperplasia, hyperkeratosis, dysplasia (mild, moderate, or severe), and
in situ or invasive cancer (well-, moderate-, or poorly-differentiated).
4.2.3 Imaging
Optically sectioned fluorescence images of the samples were obtained using an
inverted Lecia TCS 4D laser scanning confocal microscope, equipped with a Kr/Ar laser
providing excitation at 647 nm and a 665 nm long-pass filter.  Images were acquired with
a 40x oil-immersion objective with a numerical aperture of 1.0 and working distance of
80 µm.  The laser power for image acquisition varied between 3-30 µW.  Z-series stacks
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of images were obtained, with a z-step of 1.5-3 µm and 5-30 images per stack.  The
contrast, brightness, line averaging, integration time, and pinhole size remained constant
for all acquisitions.
4.2.4 Image Processing
MATLAB (the MathWorks, Inc, Natick, MA) code was written to detect the
fluorescently-labeled edges of the epithelium in the images and convert the edges into a
mask.  This mask was then applied to the original image so only information from the
fluorescently-labeled epithelium was obtained.  The mean fluorescence intensity (MFI)
for the fluorescent portions of each image in each stack was obtained by dividing the
image by the laser power at the time of acquisition.  In cases where fluorescently-labeled
cells occupied the entire field of view, the MFI was calculated for the entire image
without using edge detection.
4.2.5 Diagnosis Using Mean Fluorescence Intensity
MFI was used to determine if there was a correlation between fluorescence and
pathological diagnosis.  In addition, the epithelium was broken down into three layers,
basal, intermediate, and surface, to determine if MFI by epithelial layer would be a more
effective means for diagnosis.  If an image stack contained the basement membrane or
was within approximately 50 µm of the basement membrane, it was classified as basal.  If
it contained the superficial epithelium, epithelial-surface transition, or was within 50 µm
of the surface, it was classified as surface.  If no basement membrane or obvious
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superficial epithelium was present, it was classified as intermediate.  If the image stack
contained the entire epithelial layer, from the basement membrane to surface, its MFI was
added to all three categories.  In cases of invasive carcinoma, cells at the surface of the
tissue slice or within 50 µm of the surface were classified as surface.  Cells which were
obviously embedded in the stroma were classified as basal.  If the cells were not near the
surface or obviously invaded into the stroma, the image stack was classified as
intermediate.
The tissue slices prepared from the biopsies obtained from the first three patients
were labeled using a stock of the Alexa Fluor® 660 dye that was weighed out to prepare
the 1 mg/ml stock solution instead of reconstituting the entire vial in 1 ml of dH2O, as
was done with the remaining stocks of dye.  Due to the sensitivity of the scale and small
amounts of dye being weighed, the solution prepared using dye that was weighed in this
manner was less concentrated than dye prepared by using the entire contents of the vial.
In order to correct for this difference, a scaling factor was determined using the ratio of
the optical densities of two solutions, one prepared in each manner.  The fluorescence
intensities calculated for the first three patients were multiplied by this scaling factor.
In assigning a classification to a biopsy, hyperkeratosis and/or hyperplasia were
considered normal.  In addition, when a diagnosis of varying degrees of severity occurred
for dysplasia or cancer, either from different sections from the same biopsy having a
different diagnosis or a single section having focal areas of a different diagnosis, then the
biopsy was classified according to the most severe of the diagnoses.  For example, a
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biopsy that had mild to moderate dysplasia was classified as moderate dysplasia and a
biopsy that had moderately-differentiated cancer and moderate dysplasia was classified as
moderately-differentiated cancer.  However, if a biopsy contained both benign and
malignant tissue, it was noted as containing both rather than being classified by only the
malignant diagnosis.  For example, a biopsy containing invasive carcinoma with
overlying normal epithelium was classified as normal and cancer.
4.3 RESULTS
4.3.1 Overview of Patients
A total of 17 patients participated in this study.  Table 4-1 provides an overview
of the patients obtained in the study, with the site of biopsy and pathological diagnosis of
the clinically abnormal and normal biopsy.  The number of biopsies by pathological
diagnosis is listed in Table 4-2.
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Table 4-1 Summary of patients in clinical study, site of biopsy, and pathological
diagnosis of the clinically abnormal and normal biopsy.  Abbreviations used include floor
of mouth (FOM), buccal mucosa (BM), differentiated (diff), and moderate (mod).  No
diagnosis occurs when there is no epithelium in the sample and a pathological diagnosis
cannot be made.  A site in the center of the “site” column indicates that both the abnormal
and normal biopsy were from the same site.
Site Pathology DiagnosisPatient
Number Abnormal Normal Clinically Abnormal Clinically Normal
1 Tongue Well diff. cancer Normal











































11 Left lateral tongue Invasive moderate diff.
cancer
Hyperplasia, hyperkeratosis
12 Right tongue Right BM Normal, moderate diff.
cancer
Hyperplasia, hyperkeratosis










15 Right lateral tongue Hyperkeratosis, mild
dysplasia
Hyperplasia, hyperkeratosis










Table 4-2 Breakdown of biopsy samples by pathological diagnosis.
Pathological Diagnosis Number of biopsy samples
Normal 1






moderate to poorly-differentiated cancer
1
Hyperplasia, hyperkeratosis and dysplasia 1
Normal and cancer 2
No diagnosis 1
As is evident in Table 4-1, some of the clinically abnormal biopsies were found to
be pathologically normal, which reduced the number of overall abnormal samples in the
study.  Three of the clinically abnormal biopsies were found to be pathologically normal,
resulting in a specificity of 85% and sensitivity of 100% based on clinical impression.
4.3.2 Fluorescence Confocal Imaging
Figure 4-1 illustrates fluorescence confocal, H&E, and EGFR IHC images from
patient 4.  The clinically abnormal biopsy was from the retromolar trigone and diagnosed
as moderate dysplasia with underlying foci of moderate to poorly-differentiated cancer.
The clinically normal biopsy was from the pharyngeal wall and diagnosed as hyperplasia
and hyperkeratosis, conditions considered as normal in the oral cavity.  Figure 4-1 (a) is
representative of the fluorescence throughout the entire epithelium of the abnormal
biopsy.  The stromal to epithelial transition in a normal biopsy is shown in Figure 4-1 (b).
Fluorescence is evident near the basement membrane of epithelium from this normal
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biopsy.  The corresponding EGFR IHC sections are shown in Figure 4-1 (e) and (f) for
the abnormal and normal biopsy.  EGFR staining is strong throughout the epithelium of
the abnormal biopsy, which corresponds to what was seen in the fluorescence confocal
imaging.  In the normal biopsy, EGFR staining is strong near the basement membrane
and decreases superficially, with virtually no staining in the most superficial layer.  This
also corresponds to what was observed in confocal imaging of normal biopsies.
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Figure 4-1 Images for patient 4. Left column images are from the clinically abnormal
biopsy, which was diagnosed as moderate dysplasia with underlying foci of moderate to





















which was diagnosed as hyperplasia and hyperkeratosis.  (a) False color fluorescence
confocal image from abnormal biopsy, laser power 4 µW.  (b) False color fluorescence
confocal image from normal tissue biopsy, laser power 9 µW.  The white line indicates
the basement membrane.  (c) and (d) Corresponding H&E images for abnormal and
normal biopsies, respectively.  (e) Abnormal EGFR IHC.  Staining is present throughout
the entire epithelium.  (f) Normal EGFR IHC.  Staining is strong near the basement
membrane and decreases to virtually no staining in the superficial epithelium.
Fluorescence images taken with 40x objective, scale bar 25 µm.  H&E and EGFR IHC
images taken with 10x objective, scale bar 100 µm.
Images from an invasive moderately-differentiated cancer from patient 6 are
shown in Figure 4-2.  The clinically normal biopsy was diagnosed as hyperplasia and
hyperkeratosis.  No clear epithelium could be distinguished in the abnormal biopsy, with
labeled cells fluorescing throughout the section (Figure 4-2 (a)).  This morphology was
confirmed by the H&E section (Figure 4-2 (b)), which revealed an invasive cancer, such
that no clear epithelium existed in the biopsy.  Figure 4-2 (c) and (d) show fluorescence
confocal images from the basement membrane and superficial layer of the normal biopsy
respectively.  As is evident from these images, fluorescence was strong near the basement
membrane and decreased in the superficial layer, which correlates well to expected
EGFR expression in normal epithelium.  The corresponding transmitted image of the
normal superficial epithelium is shown in Figure 4-2 (f).
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Figure 4-2 Images for patient 6.  Abnormal biopsy was diagnosed as invasive moderately
differentiated cancer.  Normal biopsy was diagnosed as hyperplasia and hyperkeratosis.












(b) Corresponding H&E.  Invasive cancer cells are present throughout the section.  (c)
False color fluorescence confocal image from basal layer of the normal biopsy, laser
power 7 µW.  Fluorescence is strong near the basement membrane, which is indicated by
a white line.  (d) False color fluorescence confocal image from the superficial layer of the
normal biopsy, laser power 9 µW.  Fluorescence decreases in superficial layers.  (e)
Corresponding H&E.  (f) Corresponding transmitted image of the superficial layer of the
normal biopsy.  Fluorescence images taken with 40x objective, scale bar 25 µm.  H&E
images taken with 10x objective, scale bar 100 µm.
An example of a clinically abnormal biopsy with mixed pathological diagnosis of
hyperplasia and hyperkeratosis for one tissue slice and mild dysplasia for the second
tissue since is illustrated in Figure 4-3 along with the corresponding clinically normal
biopsy, which was also pathologically normal.  Figure 4-3 (a) through (c) are the
fluorescence confocal, H&E, and EGFR IHC images for the clinically abnormal and
pathologically normal tissue slice.  Strong EGFR labeling near the basement membrane is
evident in both the IHC and fluorescence images.  Figure 4-3 (d) through (f) are the
fluorescence confocal, H&E, and EGFR IHC images for the clinically abnormal tissue
slice that was diagnosed as mild dysplasia.  Fluorescence is strong near the basement
membrane (Figure 4-3 (d)).  Thickening of the epithelial layer with dysplastic cells is
evident in the H&E image (Figure 4-3 (e)).  These same cells also stain for EGFR in the
IHC image (Figure 4-3 (f)).  Figure 4-3 (g) though (i) are the fluorescence confocal,
H&E, and EGFR IHC images for the clinically and pathologically normal biopsy.
Fluorescence is again evident in the basal layers (Figure 4-3 (g)).  The relative amount of
EGFR staining in the IHC image (Figure 4-3 (i)) is similar to that in Figure 4-3 (c).
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Figure 4-3 Images from patient 10.  A mixed pathological diagnosis was obtained for the
clinically abnormal biopsy, with one tissue slice from the biopsy containing only
hyperplastic and hypkeratotic tissue and the second tissue slice containing mild dysplasia.
(a-c) Left column images are from the tissue slice from the clinically abnormal biopsy



























image, laser power 16 µW.  White line indicates basement membrane.  (b) Corresponding
H&E.  (c) EGFR IHC.  Strong staining near basement membrane and little to no staining
in the superficial layers.  (d-f) Center column images are from the tissue slice from the
clinically abnormal biopsy diagnosed as mild dysplasia.  (d) False color fluorescence
confocal image, laser power 9 µW.  White line indicates basement membrane.  (e)
Corresponding H&E.  Thickening of the epithelial layer with dysplastic cells is evident.
(f) EGFR IHC.  Staining stronger near basement membrane than either pathologically
normal tissue slice (c and i).  (g-i) Right column images are from the clinically normal
biopsy diagnosed as hyperplasia and hyperkeratosis.  (g) False color fluorescence
confocal image, laser power 9 µW.  White line indicates basement membrane.  (h)
Corresponding H&E.  (i) EGFR IHC.  Strong staining near basement membrane with
very little staining in superficial layers. Fluorescence images taken with 40x objective,
scale bar 25 µm.  H&E and EGFR IHC images taken with 10x objective, scale bar 100
µm.
Figure 4-4 (a) and (b) demonstrate the typical amount of non-specific
fluorescence seen in the stroma.  The white line in both images indicates the basement
membrane.  Some non-specific fluorescence is present in the stroma, but it is clearly not
indicative of any cellular structure, while the staining in the epithelial layer is consistent
with a cellular pattern.
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Figure 4-4 Images from patient 8. Both the clinically abnormal and clinically normal
were diagnosed as hyperplasia and hyperkeratosis (i.e., pathologically normal).  (a) False
color fluorescence confocal image from clinically abnormal biopsy, laser power 13 µW.
(b) False color fluorescence confocal image from clinically normal biopsy, laser power 8
µW.  The white line in (a) and (b) indicates the basement membrane. Fluorescence
images taken with 40x objective, scale bar 25 µm.
4.3.3 Image Processing Example
The results of the Matlab code used to determine the edge of the fluorescently-
labeled epithlieum and the mask created using these edges are illustrated in Figure 4-5 for
three successive images in a z-series stack from the abnormal biopsy for patient 4.  In
Figure 4-5 (a) through (c), the white lines indicate the edges chosen by the Matlab code.
The region determined by those edges was converted to a mask as shown in Figure 4-5
(d) through (f).  The solid red region indicates the pixels that were assigned a value of 1





When the mask was multiplied with the original image, only fluorescence information
from the labeled epithelial region was considered for MFI calculations.
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Figure 4-5 Example of edge detection and mask determined using Matlab code from
three successive images from a z-series stack of the abnormal biopsy from patient 4.  (a)-








4.3.4 Diagnosis Using Mean Fluorescence Intensity
In order to illustrate interpatient variation, the ratio of the MFI of all image stacks
from the clinically abnormal and normal biopsies from each patient was determined.
This ratio was then plotted using the pathological diagnosis of the clinically abnormal
biopsy.  In cases where both the clinically abnormal and clinically normal biopsy were
pathologically normal, the ratio was still calculated by dividing the MFI of the clinically
abnormal biopsy by the MFI of the clinically normal biopsy and this ratio plotted using
the normal pathological diagnosis of the clinically abnormal biopsy.  The plot of the ratio
of the MFI of the clinically abnormal to clinically normal biopsy by diagnosis of the
clinically abnormal biopsy and patient number as shown in Figure 4-6.  Patient 3 is
omitted from this plot because no diagnosis was obtained for the clinically normal biopsy
so a ratio could not be calculated.  The ratio for moderate dysplasia and cancer was
typically greater than 2, except for patient 17, which had a pathological diagnosis of well-
differentiated cancer and a ratio slightly less than 2.  Patients with mixed diagnosis of
normal and cancer (patients 12 and 16) or normal and dysplasia (patient 10) also had a
ratio less than 2.  The presence of normal tissue in the abnormal biopsy may have






















































Figure 4-6 Plot of the ratio of the mean fluorescence intensity from the clinically
abnormal to clinically normal biopsy from the same patient. Patient 3 is not included
since no diagnosis was obtained for the clinically normal biopsy.  Diagnosis for each
patient is based on the diagnosis from the clinically abnormal biopsy since all clinically
normal biopsies were confirmed to be pathologically normal (hyperplasia and
hyperkeratosis).  Biopsies classified as normal and cancer or normal and dysplasia had a
mixture of both normal and cancerous or dysplastic tissue in the H&E sections.
Based on the confocal images and EGFR IHC stained sections, it became evident
EGFR expression varied based on location within the epithelium and this variation
differed for normal and cancerous tissue.  For example, in the basal layers of normal
tissue, the cells stained strongly for EGFR in the IHC section, which was reflected in the
confocal images.  However, in the superficial layers of normal tissue, there was very little
EGFR staining while in samples of cancerous tissue, EGFR staining was strong
throughout the epithelium. If the confocal imaging results followed the trend seen in the
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EGFR IHC, it was assumed that the greatest differences in MFI between normal and
cancerous tissue would be seen in the surface layer.  Therefore, the MFI was classified by
epithelial layer (basal, intermediate, or surface) to determine if this would reveal greater
intensity differences between normal and cancerous tissue.  Breaking down the MFI by
epithelial layer revealed that the MFI of the surface layer separated cancer and moderate
dysplasia from normal, hyperplasia, and hyperkeratosis the most effectively as
demonstrated in Figure 4-7.  The clinically abnormal biopsies from patients 8, 9, and 12
did not have any images from the surface layer and are therefore not shown in the plot.
Patient 5 is also excluded because neither the clinically abnormal or clinically normal
biopsies had images from the surface layer.  Generally, the MFI of the surface layer was
greater than 6 for the samples diagnosed as moderate dysplasia or cancer.  The abnormal
biopsy from patient 17, which had a pathological diagnosis of well-differentiated cancer,
had a surface MFI of slightly less than 6.  The abnormal biopsies with mixed pathological
diagnoses of normal and cancer or normal and dysplasia also had a surface MFI of less
than 6.  In addition, all the abnormal biopsies with a pathological diagnosis of mild















































Figure 4-7 Diagnosis using the mean fluorescence intensity from the surface epithelium.
In three cases, only one biopsy is shown per patient (patients 8,9, and 12).  Both the
clinically abnormal and clinically normal biopsies from patient 5 are also omitted.
The ratio of the MFI from the surface and basal layers versus the MFI for the
entire epithelial is plotted in Figure 4-8 for biopsies diagnosed as normal, hyperplasia,
hyperkeratosis, or dysplasia.  Because there is no true superficial or basal epithelium in
carcinoma tissue, this ratio was not calculated for samples diagnosed as cancer.
Moderate dysplasia was well separated from the normal, hyperplasia, and hyperkeratosis
samples, but mild dysplasia and the sample with a mixed diagnosis of normal and
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Figure 4-8 Plot of the ratio of the mean fluorescence intensity from the surface layer to
basal layer versus the mean fluorescence intensity for the entire epithelium for normal,
hyperplasia, hyperkeratosis, and dysplasia biopsies.
4.4 DISCUSSION
Epidermal growth factor receptor is a relatively well-established molecular
marker that has demonstrated great promise for use as a target in diagnosing epithelial
cancer.  Other studies which have investigated correlation of EGFR expression and tumor
staging have used traditional molecular biology or protein biochemistry techniques such
as western blot or ligand assays which involve homogenization of the tissue sample to
measure levels of EGFR expression (27-31).  In contrast, we are interrogating EGFR
expression in whole tissue sections such that expression by epithelial location can be
investigated.
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We have found that tissue slices taken from oral cavity biopsies can be labeled for
EGFR using the fluorescence contrast agent.  Fluorescence correlated well with EGFR
IHC, indicating that the contrast agent was likely targeting EGFR as expected.  EGFR
expression was detected in normal tissue as well as the abnormal tissue; however, this
was expected since EGFR is a growth factor that is expressed in any rapidly proliferating
cell.  In normal epithelial tissue, the basal layer is the source for new cells and is
constantly dividing.  Therefore, it is not surprising that the cells in the basal layer would
express high levels of EGFR regardless of malignancy.  As cells from the basal layer
migrate upward and differentiate, proliferation decreases.  This would be reflected in a
decrease in expression of EGFR.  One of the hallmarks of cancer is a failure of cells to
differentiate and continual proliferation of cells throughout the epithelium, rather than in
just the basal layer.  So it would be expected that in cancerous tissue EGFR expression
would be high throughout the epithelium rather than in just the basal layer.  By using a
fluorescence contrast agent to evaluate EGFR expression, intensity of the optical signal
can be used to determine relative levels of EGFR expression.  These patterns of EGFR
expression were reflected in the fluorescence confocal imaging, where fluorescence was
strong throughout the epithelium of abnormal tissue and in the basal layer of normal
tissue but much lower or virtually non-existent in superficial layers of the normal tissue.
Overall, the MFI obtained from abnormal tissue was higher than the
corresponding normal biopsy from the same patient.  This is illustrated in the ratio of
MFI of the clinically abnormal to clinically normal biopsy from a patient.  Using a ratio
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of 2, the majority of biopsies classified as moderate dysplasia or cancer can be separated
from normal, hyperplasia, and hyperkeratosis.  The biopsies with a mixed pathological
diagnosis or mild dysplasia do not have a ratio greater than 2 and therefore do not
separate from the normal pathological diagnoses.  Figure 4-6 shows that it may be
possible to use the ratio of the MFI of a clinically abnormal site to clinically normal site
to diagnose moderate dysplasia or cancer.  Eliminating interpatient variation by using the
clinically abnormal to clinically normal MFI ratio from a single patient may be critical
since EGFR levels may vary from patient to patient dependent on other factors such as
tobacco and alcohol abuse.  For example, EGFR expression in normal epithelia adjacent
to tumor in patients who smoke or drink is higher than in patients who do not smoke or
drink (35), so it is possible that pathologically normal tissue from a patient who smokes
or drinks would have higher EGFR expression than pathologically abnormal tissue from a
patient who does not smoke or drink.  Assuming that the increase in EGFR expression is
seen in all tissue, regardless of malignancy, for patients who smoke or drink, taking the
ratio of their own abnormal to normal tissue would normalize for the increase in EGFR
expression.  This would then allow samples from different patients to be compared,
regardless of the exposure to etiological agents such as tobacco and alcohol, so that a
uniform demarcation could be used to identify a malignant diagnosis.
In addition to attempting to classify tissue based on the ratio of the MFI of the
clinically abnormal to clinically normal, fluorescence by epithelial layer was also
investigated.  When considering the MFI from only the surface layers, biopsies classified
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as moderate dysplasia or cancer generally had a much higher MFI than those classified as
normal, hyperplasia, or hyperkeratosis.  This is not surprising, since in normal tissue the
superficial layer likely expresses very little EGFR.  Mild dysplasia also had a lower
surface MFI than moderate dysplasia or cancer.  In mild dysplasia, abnormal cells only
occupy the lower one-third of the epithelium, so the superficial layers do not contain
abnormal cells which would have high levels of EGFR expression.  The superficial layer
of mild dysplasia resembles normal tissue, therefore the cells in the surface layer of mild
dysplasia probably express very little EGFR.  This probably explains why mild dysplasia
cannot be separated from normal, hyperplasia, or hyperkeratosis using the surface MFI.
Biopsies with a mixed pathological diagnosis of normal and cancer or normal and
dysplasia also had a lower surface MFI than moderate dysplasia and cancer.  This may be
due to the presence of normal tissue, which would reduce the overall surface MFI of the
clinically abnormal biopsy.
Plotting the ratio of MFI of the surface layer to the basal layer against the MFI of
all epithelial layers provided fairly good separation between moderate dysplasia and
normal, hyperplasia, or hyperkeratosis.   Mild dysplasia could not be separated from
normal, hyperplasia, or hyperkeratosis using this method.  Again, this is likely the result
of the superficial layers of mild dysplasia resembling normal tissue.  In addition, the basal
layer of mild dysplasia probably resembles normal tissue with respect to EGFR
expression since the basal layers of normal tissue is comprised of rapidly proliferating
cells with high levels of EGFR expression.  Therefore, the lack of a difference between
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mild dysplasia and normal tissue when looking at the ratio of the MFI of the surface to
basal layer is not unexpected.
It may be more clinically relevant to use only the surface layers of the epithelium
for diagnostic purposes.  Mild dysplasia, which affects the lower one-third of the
epithelium, is not highly indicative of an early malignant process and has the potential to
resolve without treatment (13).  In contrast, severe dysplasia, which affects the entire
epithelium, can be considered early malignancy rather than pre-cancer because it often
coexists with carcinoma in situ (13).  In order to avoid overtreatment, which may result in
unnecessary surgery for the patient and increases the cost of healthcare, it may be better
to focus on diagnosing moderate to severe dysplasia as early indicators of cancer.  In
moderate to severe dysplasia, only the upper one to two thirds of the epithelium will
contain possibly malignant cells, so targeting the superficial layers of the epithelium may
be more specific for more advanced stages of dysplasia.
Figure 4-7 and Figure 4-8 demonstrate that the use of the surface MFI or ratio of
MFI from the surface to basal layer can be used to separate moderate dysplasia and
cancer from normal, hyperplasia, and hyperkeratosis.  While mild dysplasia cannot be
separated from normal tissue, it may not be important to be able to diagnose mild
dysplasia since it is of less clinical concern than advanced stages of dysplasia or cancer.
With advances in optical technology, the optical signal can even be detected in
vivo using spectroscopy or confocal microscopy.  Numerous studies have investigated the
use of in vivo fluorescence spectroscopy to diagnose malignancy in the oral cavity based
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on autofluorescence (55, 58, 79, 81, 82, 84, 85).  The techniques implemented in these
studies could easily be adapted to the use of an exogenous contrast agent by modifying
the excitation source and emission filters.  Further, the contrast agent may even be better
suited to in vivo use due to its longer excitation wavelength, which avoids many of the
absorbers and scatterers present in the tissue at the optimal wavelengths for
autofluorescence (300-440 nm) (58, 81-85).  Also, the quantum yield of the contrast
agent is higher than that of the endogenous fluorophores, resulting in a better optical
signal.  In vivo confocal imaging has been achieved using fiber-based probes (88-93).
Fluorescence in vivo confocal microscopes are also commercially available from
OptiScan Imaging Limited (Victoria, Australia) and Mauna Kea Technologies (Paris,
France).
Optical techniques in vivo may even be enhanced by using the fluorescence
intensity of the contrast agent in the superficial layers of tissue rather than throughout the
entire epithelium as a diagnostic criteria.  Angled illumination geometry can be used for
depth-dependent spectroscopy measurements (109, 110), allowing measurements from
only the superficial layer.  In vivo microscopy requires that the images be acquired en
face, but the depth of in vivo confocal microscopy can also be controlled, and the most
superficial layers would be the first to be imaged and should also be the easiest to image.
In both cases, signal should be relatively high from the superficial layer due to
penetration limitations into the tissue.
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Classifying by MFI did not have 100% success in separating dysplasia and cancer
from the normal biopsies in any of the three methods used for diagnostic classification.
This could be due to the focal nature of oral cancer, where malignancy can coexist with
normal tissue in a very small area as was seen with three of the patients in the study.  In
these cases, the abnormal biopsy did not classify well.  However, pathology confirmed
that the sections contained both normal and malignant tissue, which may have resulted in
a lower overall MFI.
This study reveals that it may be important to look at EGFR expression by
epithelial layer rather than expression from a gross tissue sample.  Because of the optical
nature of the contrast agent, in vivo application and interrogation is feasible and would
allow for depth-dependent measurements.  In combination with fluorescence
spectroscopy or confocal microscopy, the contrast agent has possibilities to be
implemented as a screening tool for oral cancer.
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Chapter 5
A Simple and Inexpensive Fluorescence Spectroscopy System Capable
of Detecting a Molecular-Specific Contrast Agent for Diagnosis of Oral
Neoplasia
5.1 INTRODUCTION
Fluorescence spectroscopy has shown promise in distinguishing malignancy in
the oral cavity based on autofluorescence.  A number of studies in in vitro cell models, ex
vivo tissue samples, and in vivo in patients have interrogated the ability to use changes in
autofluorescence as a distinguishing characteristic of malignancy.  These studies have
found that differences in the fluorescence spectra between abnormal and normal tissue
can be used as a criteria to diagnose malignancy (55, 58, 79, 81).  In the oral cavity, the
optimal excitation wavelengths for distinguishing oral neoplasia range from 300-400 nm
(58, 81-85).
Despite the promise of utilizing autofluorescence as a means of detecting
neoplasia, there are some drawbacks.  While it is generally believed that the tissue
autofluorescence is due to endogenous fluorophores such as the reduced form of
nicotinamide adenine dinucleotide (NADH), flavins (FAD+, FMN, and riboflavin),
aromatic amino acids (tryptophan, tyrosine, and phenylalanine), collagen crosslinks, and
elastin crosslinks, the exact fluorophores contributing to fluorescence at a particular
excitation and emission wavelength are not necessarily known.  In addition, the exact
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biophysical and biochemical changes underlying the changes in autofluorescence
between abnormal and normal tissue are not known, although changes in tissue
architecture, such as thickening of the mucosa or loss of layered structure (55, 56) and/or
changes in both the concentration, form, and distribution of endogenous fluorophores and
the absorption properties of normal versus neoplastic tissue (55, 57, 58) are likely to be
underlying causes of the differences in fluorescence spectra.  In addition to uncertainty
about the biological nature of autofluorescence, the optimal excitation and emission
wavelengths for distinguishing neoplasia tend to be relatively short, limiting penetration
depth into the tissue due to increased scattering and absorption.  Autofluorescence signals
also tend to be relatively weak, photobleach rapidly, and are subject to low signal-to-
noise ratio (SNR).  Finally, the algorithms with the highest sensitivity and specificity in
distinguishing cancer and dysplasia from normal tissue generally involve multiple
excitation and emission wavelengths.  For example, Wang et al found that a classification
scheme which used two excitation wavelengths outperformed the single excitation
wavelength classification scheme in specificity and positive predictive value (56).
Heintzelman et al used an algorithm based on three excitation wavelengths and four
emission intensities to achieve 90% specificity and 90% sensitivity(58).  Because of the
multiple excitation and emission wavelengths required for the classification algorithms,
the spectroscopy systems associated with autofluorescence diagnosis are often large,
complicated, and expensive to construct, on the order of $75,000 for optical components
alone.
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One alternative to the shorter-wavelength emission fluorophores is the red
fluorescence of porphyrins, which has been observed in oral cancer and can be used as a
distinguishing characteristic of malignancy (111).  In addition, 5-aminolevulinic acid
(ALA) can be used to bypass the normal feedback control of production of
protoporpphyrin IX (PPIX), a precursor to the endogenous fluorophore protoporphyrin
IX (PP IX) that accumulates in certain premalignant tissues (49, 59), thereby increasing
the concentration of PP IX and increasing SNR.  Malignant tissues convert ALA to PP IX
at different rates and intensities than normal tissue (59) and tend to accumulate PP IX at a
higher rate than normal tissue.  While porphyrins and PP IX emit in the 600 nm range,
they excite in the 450 nm range, limiting penetration depth of the excitation light.  In
addition, hemoglobin absorption, which is strongest at 420, 540, and 580 nm, could
attenuate the excitation light.  Further, Heintzelman et al found that while PP IX was
associated with a larger number of abnormal samples, it was not diagnostically useful for
discriminating neoplastic tissue in the oral cavity (58).
The efficacy of fluorescence spectroscopy can be improved by coupling with
molecular-specific contrast agents.  Use of an exogenous contrast agent has some
advantages over relying on endogenous fluorescence.  First, the optical properties of the
fluorophore can be carefully chosen, to avoid wavelength regions where there is strong
absorption, scattering, or autofluorescence in tissue and to increase SNR.  Second,
because the target of the molecular-specific contrast agent is known, the biological
mechanism being targeted is known.  Finally, because an exogenous contrast agent is
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being used, the optimal excitation and emission wavelengths are known and a simple
spectroscopy system and algorithm can be used for distinguishing abnormal from normal
tissue.
Previously, we developed a molecular-specific contrast agent targeting epidermal
growth factor receptor (EGFR), which is overexpressed in a number of human
malignancies including bladder, breast, cervix and vulva, glioma, lung, and head and
neck tumors (22-24), and demonstrated its efficacy in targeting oral squamous carcinoma
cells of the buccal mucosa in monolayer, in multilayer tissue constructs, and in fresh
tissue slices obtained from oral cavity biopsies (108).  In this study, we have coupled the
contrast agent with a simple fluorescence spectroscopy system to demonstrate the ability
of an inexpensive, easily built, and easy-to-operate spectroscopy system to detect the
optical signature of a molecular marker indicative of cancer progression.
5.2 MATERIALS AND METHODS
5.2.1 Spectroscopy System
The design of the spectroscopy system is illustrated in a block diagram in Figure
5-1.  Figure 5-2 is a photograph of the actual system.  The spectroscopy system consists
of commercially obtainable components, the majority of which were purchased from
Ocean Optics, Inc (Dunedin, FL).  The S2000 spectrometer is equipped with a 600
lines/mm grating blazed at 400 nm with best efficiency (>30%) in the range of 250-800
nm, a detector collection lens, and a A/D board to allow USB or serial connection to a
computer.  The CCD of the spectrometer has 2048 elements at 12.5 µm x 200 µm per
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element.  The slit size of 100 µm gives a spectral resolution of 3.8 nm.  As given by
Ocean Optics, the spectral resolution is determined by the dispersion of the spectrometer
(equation 1) and the resolution (equation 2) as shown in equation (3).
Dispersion (nm/pixel)  = spectral range of grating (nm)/# of detector elements (pixel) (1)
Resolution (pixel) = value from slit size/fiber diameter chart given by Ocean Optics    (2)
Spectral resolution (nm) = dispersion (nm/pixel) x resolution (pixel)         (3)
The grating in the spectrometer has a spectral range of 650 nm and the CCD has
2048 elements, giving a dispersion of 0.31738 nm/pixel.  The resolution for a 100 µm slit
given by Ocean Optics is 12.0 pixels, giving a final spectral resolution of 3.8 nm.
For delivery and collection of light, the spectrometer is coupled to a R400-7
reflection probe, consisting of a 400 µm core collection fiber surrounded by six 400 µm
core illumination fibers with a numerical aperture of 0.22.  A filter holder is placed after
the breakout in the collection fibers with a 695 nm bandpass filter with a 55 nm pass band
(Omega Optical, Brattleboro, VT) to filter out extraneous excitation light and a 400 µm
core patch fiber is used to connect the filter holder and spectrometer.  Excitation light is
provided by a 633 nm HeNe laser (output power 0.95 mW, JDS Uniphase, San Jose, CA),
which is first focused to a spot size corresponding to the size of the illumination fibers
using a plano-convex lens (efl 25 mm, Edmund Optics, Barrington, NJ) and passed
through a 632.8 nm laser line filter (Edmund Optics) before coupling to the illumination
fibers.  The probe was held in an optical mount attached to a micrometer translation stage
so that the separation distance between the probe and sample could be controlled.
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Figure 5-1 Block diagram of spectroscopy system.


































The contrast agent is described in detail in (108), but will be briefly reviewed
here.  The antibody used in the contrast agent was a biotinylated mouse monoclonal anti-
human EGFR (clone 111.6, 200 mg/ml, LabVision NeoMarkers, Fremont, CA).  Alexa
Fluor® 660 streptavidin (Molecular Probes, Eugene, OR) was used as the far-red
fluorescent marker. Alexa Fluor® 660 streptavidin has a broad absorption peak with a
maximum at 669 nm, but can also be excited at 633 nm or 647 nm.  Its emission
maximum is at 690 nm with a relative quantum yield of 0.88 compared to 7-hydroxy-9H-
(1, 3-dichloro-9, 9-dimethylacridin-2-one) (DDAO).  Alexa Fluor® 660 streptavidin has
a degree of labeling of 4.7 moles of dye per mole of protein using an ε of 110,000 cm-1
M-1 at the absorbance maximum (all information on Alexa Fluor® 660 streptavidin as
reported by Molecular Probes in the Certificate of Analysis for lot #65C1).
5.2.3 Pre-labeled Mutlilayer Tissue Constructs
Multilayer tissue constructs made up of Sq/CCY1 cells, a squamous carcinoma of
the buccal mucosa (kindly provided by Reuben Lotan at the Univesity of Texas M.D.
Anderson Cancer Center) already labeled with the contrast agent for EGFR were made to
represent a tissue sample in which the entire epithelial layer is fluorescently tagged by the
contrast agent.  Cells were labeled in suspension as described in (108).  After labeling,
cells were formed into multilayer tissue constructs by resuspending the cells in solution
of collagen (Roche Applied Science, Indianopolis, IN), reconstituted in 0.2% sterile
acetic acide, 0.2 M HEPES, 10x phosphate buffered saline (PBS), and 1x PBS, final pH
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7.4.  The cell-collagen solution was pipetted into a 9 mm diameter, 2.5 mm depth silicone
isolator (Grace Bio-Labs, Bend, OR) and allowed to solidify at 37oC.  The final thickness
of the multilayer construct was approximately 2.5 mm and the final cell concentration
was approximately 80 million cells/mL.  In addition to the EGFR-labeled sample, three
control samples were also prepared: cells labeled with a normal mouse IgG (Vector
Laboratories, Burlinghame, CA), cells labeled with only the Alexa Fluor® 660
streptavidin dye, and unlabeled cells.
5.2.4 Multilayer Tissue Constructs Labeled in the Presence of Permeability-
Enhancing Agents
We previously demonstrated that labeling of multilayer tissue constructs can be
achieved to greater depths and with greater intensity in the presence of a permeability-
enhancing solution of 5% dimethyl sulfoxide (DMSO) as compared to PBS.  Multilayer
tissue constructs of SqCC/Y1 cells were prepared in 6.5 mm diameter Costar Transwell
inserts (VWR, West Chester, PA) as described in (108) and allowed to grow for 14-21
hours in a 37oC incubator with 5% CO2.  Multilayer tissue constructs were labeled for
EGFR or using the normal mouse IgG control in the presence of 5% DMSO or PBS as
described in (108).  An additional control of an unlabeled multilayer tissue construct was
also prepared.
5.2.5 Fresh Tissue Slices
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To test the ability of the spectroscopy system to detect optical signal in an actual
tissue sample, tissue slices prepared from paired clinically abnormal and normal biopsy
samples from the confocal imaging study described in Chapter 4 were also measured.
The biopsies were obtained from consenting patients at the University of Texas M.D.
Anderon Cancer Center with clinical protocols approved by the Institutional Review
Boards at the University of Texas M.D. Anderson Cancer Center and the University of
Texas at Austin.  Tissue slices were prepared and labeled as described in (108).
5.2.6 Spectroscopy Measurements
Spectroscopy measurements were obtained using OOIBase32 Spectrometer
Operating software provided by Ocean Optics.  Before obtaining measurements, the
HeNe laser was warmed up for at least 20 minutes, and the power was measured after the
focusing lens, laser line filter, and probe using a Newport Optical power meter (model
1830-C, Irvine, CA).  In addition, a global reference was taken with no sample in the path
and a global dark was obtained using a dark background.  Samples were transferred to a
quartz slide for measurements.
For the multilayer tissue construct samples, five spectra were averaged with an
integration time of 1.5 s each.  Spectra were also corrected for electrical dark with the
global dark subtracted.  Measurements were taken with the probe touching the multilayer
tissue construct and at distances 1, 2, 3, 4, and 5 mm away from the surface of the
multilayer tissue construct.  For the pair of tissue slices, a single spectra was obtained for
each sample with a 5 s integration time with a separation distance of 3 mm from the
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probe surface.  Spectra were also obtained from the quartz slide and a frosted cuvette as
controls.
5.2.7 Signal-to-Noise Ratio
SNR for each spectra was calculated using the method presented by Trujillo et al
(112).  The goal of this method is to separate the noise present in the measured spectrum
from the true signal.  To estimate the true spectrum, adjacent pixels are summed and the
spectrum is resampled in a technique known as binning.  A moving average window of
10 data points (approximately 3 nm) was applied to each spectrum, providing a binned
signal which was subtracted from the original data, giving an estimate of the noise as
shown in equation (4).  A window of 3 nm was chosen because the data collected by the
spectrometer was oversampled at approximately 0.3 nm while the true resolution of the
system was only 3.8 nm.  SNR was estimated by computing the local standard deviation
of the noise, using the same moving window as used to calculate the binned spectra, and
dividing the binned spectra by the local standard deviation as shown in equation (5).
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As expected, there was a loss of power after each optical component in the
system.  From day to day, the power remained extremely constant.  Table 5-1 gives the
typical power after the lens, laser line filter, and probe.
Table 5-1 Power in system after each optical component.
Location in System Power (mW)
After lens 0.8
After laser line filter 0.36
After probe 0.18
Power delivered to the sample is also a function of separation distance from the
probe.  This is due to the fact that the illumination light is delivered via six fibers.  When
the probe tip is close to the power meter, the illumination cones of the fibers do not
overlap, resulting in a decrease in power.  As the separation between the probe tip and the
power meter increases, the illumination cones begin to overlap and the subsequent power
increases, until the illumination cones fully overlap and the power remains relatively



















Figure 5-3 Power as a function of separation distance from the probe.
5.3.2 Spectroscopy Measurements of Pre-labeled Multilayer Tissue Constructs
The optical signal from the multilayer tissue constructs prepared using SqCC/Y1
cells labeled with the EGFR contrast agent was easily detectable compared to the IgG,
Alexa Fluor® 660 only, and unlabeled controls.  Figure 5-4 illustrates the spectra from
the samples for the various separation distances.  In all cases, the EGFR sample had a
much stronger optical signal, 12-31x higher than the IgG sample, 8-23x higher than the
dye only sample, and 13-32x higher than the unlabeled sample across all the separation
distances.  Minimal signal was obtained from the quartz slide or frosted cuvette at all
separation distances.  The signal from the EGFR sample was 9-27x higher than that from
the quartz slide and 14-32x higher than that from the frosted cuvette.  An overlay plot of
the EGFR samples at the various separation distances is shown in Figure 5-5, along with
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a plot of the maximum intensity at each separation distance.  The maximum intensity
occurs at approximately 690 nm at all separation distances.  The intensity increases with





Figure 5-4 Spectra from multilayer tissue constructs prepared using SqCC/Y1 cells
labeled using the EGFR contrast agent at various separation distances from the surface.
Cells labeled using the EGFR contrast agent (blue) have a stronger optical signal than
those labeled using the IgG control (red), Alexa Fluor® 660 (AFS) dye only (green), and
unlabeled cells (pink), which have virtually no optical signal.   (a) Probe touching surface




Figure 5-5 (a) Overlay plot of multilayer tissue constructs prepared using SqCC/Y1 cells
labeled using the EGFR contrast agent.  (b) Maximum intensity at each separation
distance.  Signal increases with increasing separation distance up to 2 mm and then
decreases.
The smoothed spectra generated by binning in the SNR calculations and the SNR
as a function of wavelength is shown in Figure 5-6.  The separation distance with the
strongest optical signal is shown in (a) and (b) and the weakest optical signal is shown in
(c) and (d).  At the maximum emission wavelength at a separation distance of 2 mm, the
SNR is 67 while the maximum SNR is 108 (Figure 5-6 (b)).  Even with decreased optical
signal, the SNR is still approximately 20 at the peak emission wavelength with a




Figure 5-6 (a) and (c) Original (blue) and smoothed (red) spectra used to calculate SNR
for multilayer tissue constructs prepared using SqCC/Y1 cells labeled using the EGFR
contrast agent.  (b) and (d) SNR as a function of wavelength.  (a) and (b) are for a
separation distance of 2 mm, which had the strongest optical signal.  (c) and (d) are for
the probe touching the multilayer tissue construct, which had the weakest optical signal.
5.3.3 Spectroscopy Measurements of Multilayer Tissue Constructs Labeled in the
Presence of Permeability-Enhancing Agents
The spectra for multilayer tissue constructs labeled in the presence of
permeability-enhancing agents at various separation distances are illustrated in Figure
5-7.  As expected from previous confocal imaging results (108), the multilayer tissue
construct labeled in the presence of 5% DMSO using the EGFR contrast agent had the
strongest optical signal.  While the signal from the sample labeled using the EGFR
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contrast agent in PBS had a higher signal than the two IgG controls, it was 3-5x weaker
than the 5% DMSO sample.  The two IgG controls had about the same signal for both 5%
DMSO and PBS.  For the samples labeled in 5% DMSO, the EGFR sample had a signal
4-10x higher than the IgG sample.  For the samples labeled in PBS, the EGFR sample
had a signal 2-3x higher than the IgG sample.  The unlabeled sample had very little
signal, with the samples labeled using the EGFR contrast agent having a signals 7-35x
and 3-9x higher respectively for 5% DMSO and PBS.  In addition, the frosted cuvette had
virtually no signal at all separation distances.  The signal from the samples labeled with
the EGFR contrast agent were 10-46x and 3-12x higher for 5% DMSO and PBS
respectively.  Figure 5-8 shows an overlay plot of the multilayer tissue constructs labeled
using the EGFR contrast agent at the various separation distances and the maximum
intensity at each separation distance.  (a) and (b) were labeled in the presence of 5%
DMSO and (c) and (d) were labeled in the presence of PBS.  Again, the peak intensity
occurs at a wavelength of approximately 690 nm at all separation distances for both 5%






Figure 5-7 Spectra from multilayer tissue constructs labeled using in the presence of the
permeability-enhancing agent, 5% DMSO.  Multilayer tissue constructs were labeled
using the EGFR contrast agent in the presence of 5% DMSO (blue) and PBS (green),
using the IgG control in the presence of 5% DMSO (red) and PBS (pink), and left
unlabeled (black).  The optical signal from the two samples labeled using the EGFR
contrast agent is higher than those labeled using the IgG control or left unlabeled, with
the multilayer tissue construct labeled in the presence of 5% DMSO having a stronger
signal than that labeled in the presence of PBS. (a) Probe touching surface (b) 1 mm




Figure 5-8 Overlay plot of multilayer tissue constructs labeled in the presence of 5%
DMSO (a) and PBS (c) using the EGFR contrast agent.  Maximum intensity at each
separation distance for the 5% DMSO sample (b) and PBS sample (d).  The signal
increases until a separation distance of 3 mm and then decreases in both cases.
The smoothed spectra and SNR as a function of wavelength are illustrated in
Figure 5-9 for 5% DMSO and in Figure 5-10 for PBS.  In both figures (a) and (b) are
from separation distance with the strongest optical signal while (c) and (d) are from the
separation distance with the weakest optical signal.  For a separation distance of 3 mm,
the SNR is 110 at the peak emission wavelength with a maximum SNR of 169 for 5%
DMSO (Figure 5-9 (b)) and 51 at the peak emission wavelength with a maximum of 113
for PBS (Figure 5-10 (b)).  Even with the noisiest signal, the multilayer tissue construct
labeled in PBS with the probe touching has an average SNR greater than 10, with an SNR
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of 11 at the peak emission wavelength and a maximum SNR of 32 (Figure 5-10 (d)).  The
SNR of the weakest optical signal for 5% DMSO is 42 at the peak emission wavelength
with a maximum of 77 (Figure 5-9 (d)).
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Figure 5-9 (a) and (c) Original (blue) and smoothed (red) spectra used to calculate SNR
for multilayer tissue constructs labeled in the presence of 5% DMSO using the EGFR
contrast agent.  (b) and (d) SNR as a function of wavelength.  (a) and (b) are for a
separation distance of 3 mm, which had the strongest optical signal.  (c) and (d) are for




Figure 5-10 (a) and (c) Original (blue) and smoothed (red) spectra used to calculate SNR
for multilayer tissue constructs labeled in the presence of PBS using the EGFR contrast
agent.  (b) and (d) SNR as a function of wavelength.  (a) and (b) are for a separation
distance of 3 mm, which had the strongest optical signal.  (c) and (d) are for the probe
touching the multilayer tissue construct, which had the weakest optical signal.
5.3.4 Spectroscopy Measurements of Fresh Tissue Slices
Spectra obtained from tissue slices prepared from a clinically abnormal and
clinically normal biopsy pair are shown in Figure 5-11.  The signal from the tissue slices
labeled using the EGFR contrast agent is higher than that from the IgG control, though
there is detectable fluorescence from both IgG controls.  The pathological diagnosis for
the clinically abnormal biopsy was a mixture of hyperkeratosis and mild to moderate
dysplasia and the pathological diagnosis for the clinically normal biopsy was hyperplasia
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and hyperkeratosis.  The peak emission wavelength for both the EGFR samples is 690
nm.  Figure 5-12 gives the smoothed spectra and SNR for the abnormal ((a) and (b)) and
normal ((c) and (d)) tissue slices labeled using the EGFR contrast agent.  The SNR is 51
and 41 for the abnormal and normal samples respectively at the peak emission
wavelength (Figure 5-12 (b) abnormal and (d) normal).
Figure 5-11 Spectra from tissue slices prepared from abnormal and normal biopsies from
the oral cavity.  Signal from both the abnormal (blue) and normal (red) tissue slices
labeled using the EGFR contrast agent is higher than the IgG control samples from the





Figure 5-12 (a) and (c) Original (blue) and smoothed (red) spectra used to calculate SNR
for abnormal and normal tissue slices using the EGFR contrast agent.  (b) and (d) SNR as
a function of wavelength.  (a) and (b) are from the abnormal tissue slice.  (c) and (d) are
from the normal tissue slice.
5.4 DISCUSSION
The results presented here demonstrate that an inexpensive and simple
spectroscopy system can be designed to detect the optical signal of a contrast agent
targeted for a molecular maker that could potentially be used for detection of neoplasia
with good SNR.  The inherent advantages to this type of spectroscopy system are that at a
cost of less than $5,000 for all the optical components, it is relatively inexpensive
compared to systems designed to detect multiple excitation and emission wavelengths.
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Further, the system is simple to build and maintain, and due to the size of the
spectrometer and the minimal optical components to required couple the laser to the fiber
probe and spectrometer, it can easily be made portable.  However, there are also some
disadvantages to the system which should be considered.  Because it is designed to detect
a specific contrast agent, it is limited to a single excitation wavelength and the
components of the spectroscopy system must be tailored to the emission profile of the
contrast agent.  This limits the flexibility of the system, which is inherently present in
multi-wavelength spectroscopy systems.  In addition, the system is only interrogating the
biological process targeted by the contrast agent, which limits the amount of information
that can be collected.  This may not necessarily be viewed as a disadvantage, because it is
not easy to elucidate the sources of endogenous fluorescence, and targeting a contrast
agent specific to a particular biological mechanism simplifies the interpretation of data.
In weighing the advantages and disadvantages, the purpose of the spectroscopy system
must be considered.  While it clearly is not ideally suited to autofluorescence studies,
which require multiple excitation and emission wavelengths to achieve good results, it
does perform well in targeting an exogenous molecular-specific contrast agent.
To first test how the spectroscopy system would perform with a sample where the
which was entirely labeled using the contrast agent, multilayer tissue constructs were
prepared using cells pre-labeled with the contrast agent, in addition to IgG, dye only, and
unlabeled controls.  While the control samples had very little signal, the optical signature
from the EGFR contrast agent was easily detectable.  This demonstrates that a solid
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tumor completely labeled by the contrast agent would be detectable by the spectroscopy
system.  However, it is possible that every cell in a tumor mass will not be targeted by the
contrast agent, so to continue testing of the contrast agent, multilayer tissue constructs
were labeled with the contrast agent applied from the top surface in the presence of 5%
DMSO, a permeability-enhancing agent, and PBS as a control.  Previous studies with
confocal imaging revealed that the contrast agent is able to penetrate deeper into the
multilayer tissue construct in the presence of 5% DMSO than in PBS and also has a
stronger signal.  Therefore, it was expected that the multilayer tissue construct labeled in
the presence of 5% DMSO would have a stronger optical signal due to a greater number
of labeled cells with greater intensity and the results obtained followed this assumption.
In fact, the weakest optical signal from the multilayer tissue constructs labeled in the
presence of 5% DMSO had an intensity only slightly less than the strongest optical signal
from the multilayer tissue construct labeled in the presence of PBS.  In both cases, the
EGFR contrast agent had a greater intensity than the IgG controls and unlabeled samples.
The IgG multilayer tissue constructs had nearly equivalent intensities at all separation
distances, which is not surprising since regardless of the permeability-enhancing solution,
there should only be minimal fluorescence from the IgG control.  The fluorescence that is
detected from the IgG controls is likely due to accumulation of dye at the surface of the
multilayer tissue construct and not specific labeling, as shown in (108).  Thee multilayer
tissue constructs prepared using pre-labeled cells do not show significant fluorescence
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with the IgG or dye only controls because the dye can be washed away easily before the
cells are formed into the multilayer tissue construct.
In both types of multilayer tissue constructs, the intensity of the fluorescence
signal is dependent on separation distance between the sample and probe.  This is due to
the design of the probe.  With increasing separation, there is increase in the detected
fluorescence to a certain separation distance and then a decrease in the detected
fluorescence.  This trend agrees with observations by other groups (113).  With no or
minimal separation between the probe and sample, there is no overlap between the
illumination and collection fibers, such that light must propogate laterally to be detected
by the probe (113).  With increasing separation, there is an increase in the overlap
between the illumination and collection areas and a subsequent increase in the
fluorescence detected.  However, with increasing separation, the collection efficiency
also decreases approximately inversely proportional to the separation distance (113),
which eventually leads to a reversal in the trend.
It has previously been shown that a probe geometry with overlapping illumination
and collection areas is sensitive to fluorescence from the epithelial surface while a non-
overlapping geometry is sensitive to sub-surface tissue layers (110).  While it is generally
believed that the non-overlapping geometry is more sensitive to the earliest changes
associated with neoplasia (110, 113) and also has the advantage of avoiding collecting
signal from the highly fluorescent keratin layer at the epithelial surface in oral mucosa
(110), these observations were specifically for endogenous fluorescence.  Using an
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exogenous contrast agent with different optical properties than endogenous fluorophores
will change the requirements for probing geometry in order to detect neoplasia.  The
fluorescence of keratin appears to be strongest in the 300 nm range (unpublished
observations), and may therefore not cause increase noise in tissue labeled with the
EGFR contrast agent.  Cells at superficial layers may also show an increase in EGFR
expression before displaying the metabolic changes which are detected using
autofluorescence.  Further, it may not always be desirable to probe sub-surface epithelial
layers, particularly if the detection emphasis is on severe dysplasia and in situ carcinoma
rather than mild dysplasia, which has the potential to reverse without treatment (13).
In order to test the spectroscopy system with an actual tissue sample, tissue slices
labeled with the contrast agent for confocal imaging were also measured with the
spectroscopy system.  Fluorescence signal was obtained from both the abnormal and
normal tissue slice, though there was not a significant difference in the intensities.
However, the mixture of normal and dysplastic tissue types in the clinically abnormal
biopsy may explain why the intensity of the abnormal tissue slice is not significantly
greater than the normal tissue slice.  In addition, labeling of the EGFR contrast agent in
mild to moderate dysplasia is expected to be less than in cancer, so more significant
differences in fluorescence intensity between a normal and cancer specimen may be seen.
As a sample for a spectroscopy system, tissue slices are not ideal because the
sample is transversely sectioned thinly (200-250 µm) for confocal imaging.  In a
transverse section of biopsy sample, both the epithelial and stromal layers will be present.
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Due to the small size of the section, and the inability to determine exact location in the
tissue slice when obtaining a measurement, the optical signal from the entire tissue slice
was obtained.  Therefore, both specific labeling in the epithelial layer and non-specific
stromal fluorescence was collected for each measurement.  The thickness of the tissue
slice is also thinner than some regions of oral mucosa, which could also lead to a
comparative decrease in the amount of fluorescence that could be collected. A better
tissue sample to use for spectroscopy measurements would be a whole biopsy, with
spectroscopy measurements taken from the surface of the biopsy sample.  However, due
to a limitation in the number of biopsies that could be obtained from patients, it was not
possible to dedicate a whole biopsy pair to the spectroscopy study.  The use of tissue
slices does demonstrate that the spectroscopy system can detect signal from a tissue
sample.  Further, it is likely that the fluorescence intensity from a whole biopsy would be
greater than that from a tissue slice.
These results demonstrate that a simple spectroscopy system coupled with a
molecular-specific fluorescence contrast agent has the ability to distinguish positively
labeled malignant sample with good SNR.  This is particularly compelling because it
would greatly increase the ability to use a spectroscopy system for diagnosis of oral




Considerations for in vivo Use of the Fluorescent Contrast Agent2
6.1 INTRODUCTION
The results presented in this dissertation have demonstrated the use of a
molecular-specific fluorescence contrast agent for use in detection of oral cancer in in
vitro biological models and ex vivo biopsy samples.  However, to utilize the full potential
of the contrast agent, it must have the ability to be used in vivo.  The combination of the
contrast agent with optical techniques such as fluorescence spectroscopy or confocal
microscopy could result in a new diagnostic technique for oral cancer.  However, to take
advantage of the non-invasive nature of optical modalities, the contrast agent would need
to be used in vivo in patients.  Without in vivo use, the fluorescence contrast agent would
not provide as much of a significant advantage over current diagnostic techniques,
because biopsy and microscopic examination of the tissue would still be required.
When considering in vivo use of the contrast agent, a number of issues must be
considered.  First among these issues are toxic effects of the contrast agent, which would
include possible cytotoxic effects of the Alexa Fluor® 660 streptavidin dye,
immunogenic effects of the antibody, and the usage of a biotin-streptavidin system and
                                                 
2 Portions of this chapter have been published previously in Hsu, E.R., E.V. Anslyn, S.
Dharmawardhane, R. Alizadeh-Naderi, J.S. Aaron, K.V. Sokolov, A.K. El-Naggar, A.M.
Gillenwater, and R.R. Richards-Kortum, 2004.  A far-red fluorescent contrast agent to
image epidermal growth factor receptor expression.  Photochem. Photobiol. 79(3), 272-
279.
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permeability-enhancing agents in vivo.  In addition, optimal time for localization of the
contrast agent to neoplasia and subsequent imaging and clearance of the contrast agent
from the tissues must also be considered for optimal use of the contrast agent in vivo.
Finally, the performance of the contrast agent under physiological conditions, most
importantly temperature, must also be examined.  Experiments were performed to assess
the effects of the dye on cell growth, morphology, and viability and to evaluate the
contrast agent under physiological temperatures, and will be described in the materials
and methods section.  The remaining issues will be discussed with respect to literature
and current clinical practices in the discussion section.
6.2 MATERIALS AND METHODS
6.2.1 Cytotoxicity, Two Day Incubation
A preliminary cytotoxicity assay of Alexa Fluor® 660 streptavidin (Molecular
Probes, Eugene, OR) was performed by incubating SqCC/Y1 cells with 1:10, 1:20, and
1:50 dilutions of the dye and no dye.  A single plate of SqCC/Y1 cells was harvested, a
viability count performed, and the plate split into 8 plates and allowed to set up for 2 days
in Dulbecco’s modified essential media/F12 (Invitrogen, Carlsbad, CA) with 5% fetal
bovine serum (FBS) (Hyclone, Logan, UT), penicillin, streptomycin, and glutamine
(Invitrogen).  The media was then removed and replaced with media containing the
appropriate dilution of dye for a total volume of 10 ml.  Two plates of each sample were
prepared.  After two days, each plate was collected and a viability count performed using
a hemacytometer and trypan blue (Sigma Aldrich, St. Louis, MO) staining.
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6.2.2 Cytotoxicity, Eleven Day Incubation
To further test the cytotoxicity of Alexa Fluor® 660 streptavidin over a longer
period of time, a similar experiment to the two day incubation was performed.  A single
plate of SqCC/Y1 cells was harvested and used to plate a 6 well tissue culture plate at a
1:8 split, ~200,000 cells/well.  After setting up for one day, the media with the various
dye dilutions was added.  In addition to the dilutions used in the two day incubation
study, 1:2 and 1:5 dilutions were added.  At days three and seven, the cells were
collected, a viability count performed, and the cells replated at a 1:4 split in media with
the same dye concentration.  On day eleven, the cells were collected and a viability count
performed.
6.2.3 Cytotoxicity, Recovery After Exposure
A final cytotoxicity test was performed to assess the effects of long-term exposure
to the dye without harvesting the cells and to assess the recovery of the cells after
exposure to the dye.  A single plate of SqCC/Y1 cells was harvested and used to plate a 6
well tissue culture plate at an low density, ~25,000 cells/well.  After setting up for one
day, the media with the dye concentrations used in the eleven day experiment was added.
On day seven, the cells were collected, a viability count performed, and the cells replated
at a 1:4 split in media with no dye.  On day eight after replating in media with no dye, the
cells were collected and a viability count performed.
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6.2.4 Performance of Contrast Agent under Physiological Temperature
MDA-MB-468 and SqCC/Y1 cells were grown in monolayer as described in
Chapter 3.  Labeling was also performed as described in Chapter 3, at both room
temperature and at 37o C.  Cells were imaged using a Lecia TCS 4D laser scanning
confocal microscopy with excitation at 647 nm and a 665 nm longpass filter.
6.3 RESULTS
6.3.1 Cytotoxicity of Alexa Fluor® 660 Streptavidin, Two Day Incubation
The Alexa Fluor® 660 streptavidin had no effect on the viability of the cells after
the two day incubation period.  All samples had a viability of 98% or higher as shown in
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Figure 6-1 Results of two day cytotoxicity experiment.  (a) Percent viability of the cells.
(b) Concentration of cells in number of cells/mL.
6.3.2 Cytotoxicity, Eleven Day Incubation
a b
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When the incubation period was extended to eleven days, with the cells split and
replated on days three and seven, the overall viability decreased.  At day three, all
samples had a viability of 94% or higher and a relatively comparable cell count as seen in
Figure 6-2 (a) and (b).  After replating, however, cells grown with the dye did not
reattach as well as cells grown with no dye.  At day seven, this was reflected in the
overall cell count, with cells grown in the presence of dye having a cell count 2-7x less
than cells grown with no dye (Figure 6-2 (d)).  The viability of cells grown in the
presence of dye had a viability of 80% or higher compared to 95% for the control cells as
shown in Figure 6-2 (c).  A similar situation was seen after the day seven split and
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Figure 6-2 Results of eleven day cytotoxicity experiment.  (a) Viability on day three,
relatively comparable among all samples.  (b) Cell concentration on day three.  (c)
Viability on day seven.  (d) Cell concentration on day seven.  Significantly lower for cells
grown in the presence of dye.  (e) Viability on day eleven.  (f) Cell concentration on day





6.3.3 Recovery After Exposure
SqCC/Y1 cells were also grown in the presence of the dye over a seven day
period without splitting to evaluate the effects of the dye without concern for cell
reattachment.  Through day four, all cells grew well with normal morphology.  Between
days five and seven, the morphology of the cells in the presence of dye began to change,
with the cells exhibiting a more spindly and isolated morphology rather than continuous
areas of confluent growth.  In addition, there was a great deal of death between days five
and seven.  This was reflected in the cell count, where cells grown in the presence of dye
had a cell count about 2x lower than the control cells (Figure 6-3 (b)).  Overall, the
viability of cells grown in the presence of dye was generally lower as well as seen in
Figure 6-3 (a).  In order to test the ability of cells to recover after exposure to the dye,
these cells were split and grown in their normal media.  The cells that had been grown
with dye did not initially reattach well, which resulted in a low overall cell count after
eight days of recovery compared to the control cells (Figure 6-3 (d)).  The overall cell
viability increased, however, with the 1:2 dilutions having the lowest viability at 88% and
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Figure 6-3 Results of recovery after exposure experiment.  (a) Viability on day seven.
(b) Cell concentration on day seven.  (c) Viability on day eight after recovery.  (d) Cell
concentration on day eight after recovery.
6.3.4 Performance of Contrast Agent under Physiological Temperature
Fluorescence under both room temperature and at 37oC for both cell lines labeled
with the EGFR contrast agent was similar.  SqCC/Y1 cells labeled using the contrast
agent and IgG control are shown in Figure 6-4 along with the corresponding DIC
transmitted images.  Cells labeled at 37oC (Figure 6-4 (c)) may show a little bit more
internalization of the contrast agent than those labeled at room temperature (Figure 6-4




of the cell still shows continuous labeling.  In addition, the IgG control did not show any
increase in fluorescence when labeling was performed either room temperature or 37oC
(Figure 6-4 (e) and (g)).
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Figure 6-4 SqCC/Y1 cells labeled at room temperature and at 37oC.  Left column are






contrast agent at room temperature, laser power 12 µW.  (c) EGFR contrast agent at
37oC, laser power 10 µW.  (e) IgG control at room temperature, laser power 7 µW.  (g)
IgG control at 37oC, laser power 9 µW.
6.4 DISCUSSION
Over a short period of time, the Alexa Fluor® 660 dye seems to have little effect
on cell viability.  As the incubation time is increased, however, the dye does have a
detrimental affect on cell growth and viability.  It appears that it may somehow interfere
with how the cell attaches to the growth substrate due to changes in the cell morphology
over time and the inability of cells to reattach effectively after splitting.  An important
caveat to the cytotoxicity studies performed here is that the cell concentration and cell
viability was assessed using hemacytometer counting, which is not extremely accurate.
However, the experiments do give a good general picture of the effects of the Alexa
Fluor® 660 dye on cell growth and viability.  Growing the cells in a 3D matrix such as
Matrigel™ instead of in plastic tissue culture dishes might reveal whether the effects of
the dye are due primarily to interference with cell adhesion.  A 3D matrix is also more
representative of the environment a cell would experience in vivo and the types of
attachments the cell would need to form with its environment.  Recovery experiments
demonstrated that cells which did survive exposure to the dye eventually recovered and
were able to grow normally after removal of the dye.  Further toxicity studies should
include animal testing to further assess the effects of the Alexa Fluor® 660 streptavidin
dye.  While detrimental effects of the Alexa Fluor® 660 streptavidin dye are evident in
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cells exposed for longer than four days, this is considerably longer exposure than would
be necessary for in vivo labeling.
Increased temperature will increase the rate of receptor internalization.  Since
previous in vitro and ex vivo experiments were performed at room temperature, the
effects of labeling at 37oC were evaluated.  Increased receptor internalization could result
in a decrease in labeling, if the receptor is internalized before targeting by the contrast
agent, or increased fluorescence internally and a decrease in fluorescence in the cell
membrane, if the receptor is internalized after targeting by the contrast agent.  Very few
differences were seen in the labeling at room temperature and at 37oC, though bright
spots of fluorescence were more evident in the cells labeled at 37oC than at room
temperature.  These spots could represent vesicles of receptors that have been
endocytosed by the cell or dense areas of receptors which are beginning the endocytosis
process.  However, there is not an associated decrease with labeling of the cell
membrane.  The lack of labeling at 37oC with the IgG control indicates that the cell is not
non-specifically taking up the Alexa Fluor® 660 dye, which would result in an increased
background.  These results are encouraging because they imply that there would be no
decrease in fluorescence intensity or increase in non-specific background fluorescence
with in vivo labeling.
Immunogenic effects of the antibody in the contrast agent can be minimized
through the use of low antibody concentrations. In the studies presented in preceding
chapters of this dissertation, a 1:10 dilution of the EGFR antibody resulted in a
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concentration of 20 µg/ml and the Alexa Fluor® 660 streptavidin dye was used at a
concentration of 31.25 µg/ml.  100 µl of each, or 2 µg of the antibody and 3.1 µg of the
dye, was used in order to label the multilayer tissue constructs, which consisted of
approximately 32 million cells.   A precancer with a 1 mm radius and 300 µm depth
consists of approximately 106 cells, so the amounts of antibody and dye used to label the
multilayer tissue constructs are theoretically sufficient for detecting a precancerous
lesion.  Cetuximab is an EGFR antibody produced by ImClone Systems (Somerville, NJ)
which is currently in clinical trials for treatment of several types of solid tumors,
including head and neck.  The current recommended dosage is an initial loading dose of
400 mg/m2 and maintenance doses of 200 mg/m2 (114).  The body surface area of a man
using the average height and weight statistics given by the CDC is 2 m2, resulting in a
Cetuximab loading does of 800 mg and maintenance does of 400 mg. Drug dosage is
difficult to directly compare to the amounts of antibody used in this study because the
goal of the Cetuximab treatment is cancer therapy rather than diagnosis and dosage is
given in terms of body surface area, but it is clear that the amounts of EGFR antibody
required for diagnostic imaging are considerably less than the amounts administered for
therapeutic reasons with tolerable side effects. While the number of cells in the multilayer
tissue construct cannot be extrapolated directly to the number of cells in an in vivo solid
tumor, these numbers indicate that the concentrations of antibody and dye being used
here are not unreasonable for clinical use.
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With respect to in vivo use of the contrast agent, questions concerning the use of
the biotin-(strept)avidin system and the various permeability enhancing agents must also
be addressed. The high affinity biotin-(strept)avidin system has been used in vivo in
radio-applications, including radioimmunodetection and therapy of cancer in humans
(115) and immunotargeting of cytotoxic molecules and cells to tumor cells (96, 116-119).
The possible drawbacks to using streptavidin for in vivo applications are that it tends to
be sequestered quickly by the kidneys (120), which could limit the amount of the
streptavidin-conjugated compound delivered to the target, and it cannot be humanized,
potentially making it more immunogenic.  Streptavidin has been modified in order to
improve its in vivo sequestration characteristics (120), however kidney localization of the
stretpavidin-labeled dye before tumor targeting is not likely to be a problem with topical
application of the contrast agent. Further, streptavidin is an analog of avidin, which has
better immunogenic characteristics but a much shorter circulatory half-life (115) and
could replace streptavidin in the contrast agent for biotin-binding.
The presence of endogenous biotin could result in false-positive staining due to
endogenous avidin-binding activity (EABA).  Studies which investigated the levels of
background EABA in tissue sections from various organ sites found levels to be high
only in tissues known to contain large biotin stores, which include liver, adipose tissue,
mammary gland, and kidney (121).  We are therefore hopeful that in the oral cavity,
EABA levels will be low and not contribute significant background.
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Topical application would be ideal for in vivo use in targeting epithelial cancers to
minimize systemic exposure to the contrast agent.  We have demonstrated that the use of
permeability-enhancing agents such as dimethyl sulfoxide (DMSO) and
polyvinylpyrooliodone (PVP) have the potential to enhance topical application.
However, the use of a permeability-enhancing agent adds an additional substance whose
biocompatibility must be considered.  Clinically, DMSO has been approved by the FDA
for use in treatment of interstitial cystitis and is delivered as a 50% solution or in a
DMSO cocktail which contains 50 cc of 50% DMSO (122). According to FDA
toxicological data for class 3 solvents, the permitted daily exposure of DMSO is 50
mg/day or approximately 500 mol/day.  500 µl of a 5% solution of DMSO contains only
0.35 mmol of DMSO.  In addition, PVP has been approved by the FDA as an excipient in
topical formulations and is used in a povidone-iodine solution ranging from 1-20% in
drugs from various pharmaceutical companies (information from the FDA Center for
Drug Evaluation and Research website).
Two pharmokinetic issues which should be considered for in vivo use of the
contrast agent are localization time to the tumor before imaging and clearance of the
contrast agent from tissue.  Most target-specific fluorescent contrast agents that have
demonstrated localization to tumors in animal models are delivered via i.v. or i.p.
injection (37, 62, 65-67).  In the case of i.v. or i.p. injection, localization time to the
tumor before imaging is critical because the contrast agent is generally being delivered
systemically through the bloodstream.  There will therefore be some delay before the
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contrast agent can be circulated to the site of the tumor.  In addition, the contrast agent
may also be taken up by other organs, such as the liver and kidney, when injected into the
bloodstream.  Some time for clearance of the contrast agent after localization to the tumor
may also be necessary to avoid background fluorescence from circulating contrast agent.
In the case of topical application, time for localization and clearance may not be as
critical.  In one scenario for use of the contrast agent as a diagnostic tool for oral cancer,
the contrast agent would be applied directly to a suspicious lesion.  Therefore, there
would be no time delay in waiting for the contrast agent to reach the tumor site.  Also,
because less tissue is exposed to the contrast agent in topical application, there may not
be as much background fluorescence from non-specific interactions.
Clearance of the contrast agent from the tissue after obtaining measurements may
also be important in order to reduce the length of exposure to the contrast agent.  Contrast
agent administered through i.v. injection that does not localize to a tumor and is
circulating in the bloodstream should be cleared by the body naturally.  It is also assumed
that if the contrast agent does localize to a tumor, that the tumor would be removed,
eliminating the contrast agent at the same time.  However, contrast agent which is taken
up non-specifically by other organs may remain in the body for a longer period of time..
Topical application would eliminate systemic exposure of the body to the contrast agent,
minimizing many of these concerns.  Finally, our contrast agent targets epithelial cancers
in the oral cavity, which should also eliminate many of the concerns regarding clearance
from the tissue.  It is very unlikely that through topical application, the contrast agent
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would be able to pass through the entire epithelial layer and portions of the stroma and
endothelial vessel walls to infiltrate into the bloodstream, so the contrast agent should
remain fairly localized to the epithelial layers of the oral cavity.  Also, there tends to be
faster overturn of epithelial cells, which may result in natural clearance of the contrast
agent through cell death and removal.
Clearly, there are somewhat complicated issues which must be addressed before
the contrast agent can be used in vivo.  However, while careful consideration must be
taken with all the issues discussed here, it is evident that in vivo use of the contrast agent
is not an unreasonable prospect.  Further studies will need to be performed to evaluate the
contrast agent before it can be used in vivo, but the experiments performed thus far and





7.1 SUMMARY OF RESULTS
The results presented in this dissertation demonstrate the use of a molecular-
specific fluorescent contrast agent in combination with fluorescence spectroscopy and
confocal microscopy.  The contrast agent is targeted against epidermal growth factor
receptor (EGFR), which is often overexpressed in oral cancer and is expressed in the
early stages of cancer, making it a good molecular target for early detection of cancer.
Currently, diagnosis of oral cancer relies on visual detection and suspicion by the treating
clinician.  Therefore, oral cancer is generally not diagnosed until it has reached advanced
stages, when morbidity and mortality is high.  The contrast agent could potentially be
used as a diagnostic tool, particularly in conjunction with a noninvasive optical technique
such as fluorescence spectroscopy.
In the third chapter of this dissertation, the contrast agent was evaluated in in vitro
biological models as a first step in testing its potential for use in diagnosis of oral cancer.
The ability of the contrast agent to image EGFR in cancer cell lines was demonstrated,
with detectable fluorescence signal using a range of antibody dilutions and incubation
times.  The ability to penetrate through 500 µm thick multilayer epithelial tissue
constructs when applied topically with permeability-enhancing agents was also
demonstrated.
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The fourth chapter expanded evaluation of the contrast agent to testing in ex vivo
biopsy samples, using fresh tissue slices from paired clinically abnormal and clinically
normal biopsy samples obtained from consenting patients.  These experiments revealed
that the biggest difference in fluorescence intensity between the abnormal and normal
samples was seen in the surface layer of the epithelium, which had decreased EGFR
expression in normal tissue due to lack of cellular proliferation.  Within a patient, a
pathologically abnormal biopsy had a greater fluorescence intensity than a pathologically
normal biopsy, which was reflected in the ratio of the mean fluorescence intensity of the
abnormal to normal.  Both the abnormal and normal ratio and the mean fluorescence
intensity of the surface layer of the epithelium provided fairly good separation between
normal and moderate dysplasia or cancer.
Expansion of the use of the contrast agent in conjunction with fluorescence
spectroscopy was explored in chapter five.  A simple fluorescence spectroscopy system
was built and designed to detect the optical signal of the contrast agent.  This ability of
this system to detect multilayer tissue constructs labeled using the contrast with good
signal-to-noise ratio (SNR) was demonstrated.  The potential of the spectroscopy system
to detect labeled tissue was also explored using fresh tissue slices.  With increased
integration time, the spectroscopy system was able to detect the optical signal of the
contrast agent in a tissue sample with good SNR.
Chapter six explored the issues which must be considered for in vivo use of the
contrast agent.  In order to fully utilize the potential of the contrast agent as a diagnostic
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tool in the oral cavity in conjunction with a noninvasive optical technique, it must be used
in vivo.  While the Alexa Fluor® 660 streptavidin dye did appear to negatively effect
cells over a long period of exposure, cells grew well in the presence of dye for up to four
days.  Labeling at physiological temperature rather than room temperature also did not
appear to have a significant effect on labeling.  Other considerations, such as
immunogenic effects of the antibody, the use of the biotin-streptavidin system and
permeability-enhancing agents, optimal time for localization, and clearance of the
contrast agent from tissue, were discussed in relation to relevant literature.  Altogether, it
appears that in vivo use of the contrast agent without detrimental effects is possible.
The research presented in this dissertation lays the groundwork for the
development of a tool that could be used in diagnosis of oral cancer.  The specificity of
the contrast agent for EGFR was demonstrated using in vitro biological models, along
with the ability to penetrate into multiple layers of epithelial cells.  The ability to use
fluorescence intensity as a diagnostic criteria was demonstrated in ex vivo biopsy
samples.  Finally, the use of a simple spectroscopy system in conjunction with the
contrast agent was demonstrated, which would be ideal as an inexpensive diagnostic tool
that could be used without specialized training.
7.2 FUTURE DIRECTIONS
While the research presented here provides a solid basis for the development of a
diagnostic tool for the early detection of oral cancer, further research must be performed
to fully evaluate the use of a fluorescence contrast agent and spectroscopy system as a
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diagnostic tool.  More samples in the ex vivo biopsy study must be obtained to ensure that
fluorescence intensity of the contrast agent can be used as a diagnostic criteria.  Ideally,
enough samples would be obtained to determine a demarcation in the abnormal to normal
ratio or surface fluorescence intensity that separates normal from cancer and dysplasia
with good sensitivity and specificity.  This study could also be expanded to evaluate the
ability of the contrast agent to aid in detection of tumor margins using both confocal
microscopy and fluorescence spectroscopy.  If the fluorescence intensity of the contrast
agent can be used to demarcate a relatively clear border for a tumor, it could be used to
determine if a tumor has been entirely resected during surgery in near real-time rather
than having to wait for a biopsy sample to be prepared for microscopic examination.
The permeability-enhancing agents have shown the ability to penetrate multiple
layers of epithelial cells in tissue constructs, but they must also be tested in actual tissue
samples to determine the depth of labeling which can be achieved.  This could be tested
using whole biopsies, by immobilizing the biopsy in agar or gelatin and applying the
contrast agent and permeability-enhancing agent on top, or possibly in an animal model.
It would also be ideal to determine if the permeability-enhancing agents were increasing
transport of the contrast agent intra- or intercellularly; in other words, if the permeability-
enhancing solution is permitting the contrast agent to pass through the cell itself or
between cell-cell junctions.
Further testing with the spectroscopy system also needs to be performed to
validate its use as a simple diagnostic tool.  If the contrast agent shows the ability to
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discriminate between normal and dysplasia and cancer with good sensitivity and
specificity based on mean fluorescence intensity, then it could easily be used in
conjunction with the spectroscopy system as a diagnostic tool.  In order to determine the
performance of the spectroscopy system in tissue, it should be tested with whole ex vivo
biopsies labeled with the contrast agent and possibly in an animal model as well.
Ultimately, if the contrast agent is approved for in vivo use, the combination of the
contrast agent and spectroscopy system as a diagnostic tool for oral cancer could be
tested in an in vivo pilot study.
In addition to the spectroscopy system, the contrast agent could also be used in
combination with fluorescence confocal microscopy.  The contrast agent would improve
the optical signal, making it easier to visual with confocal microscopy, and also would
provide an indicator for early disease.  To truly utilize the advantages of optical
techniques, an in vivo fluorescence confocal microscope would need to be developed.
Current fiber-based confocal microscopes either target reflectance or fluorescence at 488
nm only, while the contrast agent requires excitation at 633-660 nm.  Adapting a 488 nm
fiber-based confocal microscope for excitation at 633-660 nm should be a relatively
straightforward change, the primary alterations consisting of a different excitation light
source and emission filters.
Clearly, more research needs to be performed to assess both the contrast agent and
spectroscopy system.  However, the foundations presented in this dissertation are
extremely promising and exciting for a fluorescence contrast agent that could be used as
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diagnostic tool for early detection of cancer in the oral cavity.  In particular, combining
the contrast agent with a simple spectroscopy system would provide a simple diagnostic
tool at relatively low cost that could be used by personnel without specialized training to
identify suspicious lesions in the oral cavity.  The development of a true diagnostic tool
in the oral cavity that does not rely purely on the clinician’s expertise would hopefully
increase early detection of oral cancer and ultimately result in a decrease in the morbidity
and mortality associated with oral cancer.
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